# Chapter 109: Opioid Use Disorder

## The Biological and Neurological Basis of Opioid Use Disorder

## Introduction

Opioid Use Disorder (OUD) is a chronic, relapsing brain disease characterized by a problematic pattern of opioid use leading to clinically significant impairment or distress (Lee, 2024; Dydyk et al., 2021; Kolla & Hocker, 2021). The diagnosis, as outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM), is defined by a cluster of cognitive, behavioral, and physiological symptoms indicating that an individual continues using opioids despite significant substance-related problems (Franklin, 1995; Laks & Alford, 2024; Schuckit, 2016). These criteria include phenomena such as tolerance, withdrawal, a persistent desire or unsuccessful efforts to control use, and continued use despite negative consequences (Schuckit, 2016; Ungar et al., 2016). The clinical course of OUD often involves periods of exacerbation and remission, but the underlying vulnerability to relapse can persist indefinitely, a pattern similar to other chronic medical conditions like diabetes or hypertension (Dydyk et al., 2021; Schuckit, 2016).

Fundamentally, OUD is a disorder of the central nervous system (Maila et al., 2020). It is crucial to distinguish the clinical syndrome of addiction from the physiological states of tolerance and physical dependence (Hansen, 2016). Tolerance is a neuroadaptive state where a markedly increased amount of an opioid is needed to achieve the desired effect, or a diminished effect is seen with the continued use of the same amount (Laks & Alford, 2024; Leyde & Azari, 2020). Physical dependence is an adaptive state manifested by a drug-class-specific withdrawal syndrome upon abrupt cessation, rapid dose reduction, or administration of an antagonist (Hansen, 2016; Hosztafi, 2011; Smith et al., 1988). While tolerance and dependence are common features of OUD, they can also occur during appropriate, long-term medical therapy and are not, in themselves, synonymous with addiction (Campana, 2017; Hansen, 2016). Addiction, or psychological dependence, represents the most severe form of the disorder and is characterized by a compulsive drive to seek and use the drug, a loss of control over intake, and continued use despite adverse consequences (Campana, 2017; Rodriguez et al., 2017; Shah & Zaky, 2023).

The transition from voluntary, recreational, or even medically supervised opioid use to the compulsive, uncontrolled seeking and taking that defines addiction is rooted in profound and persistent neurobiological changes (Piazza & Deroche‐Gamonet, 2013; Blackwood & Cadet, 2021). These alterations occur across multiple levels, from molecular and cellular adaptations within specific neurons to large-scale functional reorganization of entire brain circuits (Nidode et al., 2024; Blackwood & Cadet, 2021). This chapter will provide a comprehensive examination of the biological and neurological basis of OUD. It will explore the primary neurotransmitter systems and neuropharmacological actions of opioids, the key brain regions and neural circuits that are dysregulated, and the genetic and molecular factors that confer vulnerability. Furthermore, it will detail the cellular and synaptic mechanisms of neuroplasticity that underlie the core phenomena of OUD—including tolerance, withdrawal, craving, and relapse—and discuss how this biological understanding informs current and future treatment strategies.

## Neurobiological Systems

The development and maintenance of OUD are critically dependent on the interaction of exogenous opioids with several endogenous neurobiological systems. Chronic opioid exposure usurps and remodels the brain's natural circuits for reward, motivation, pain, and stress, leading to the pathological state of addiction (Piazza & Deroche‐Gamonet, 2013; Koob, 2020).

### The Endogenous Opioid System and Neuropharmacology of Opioids

The human body possesses an endogenous opioid system comprising opioid peptides (endorphins, enkephalins, and dynorphins) and their corresponding receptors: the μ (mu), δ (delta), and κ (kappa) opioid receptors (MOR, DOR, KOR) (Bhatt & Gill, 2016; Smith et al., 1988). This system is integral to modulating pain, stress responses, mood, and reward (Cohen & Pickar, 1981; Sirohi et al., 2012). Exogenous opioids—including prescription analgesics like morphine, oxycodone, and fentanyl, as well as illicit drugs like heroin—exert their primary effects by acting as agonists at these receptors, particularly the MOR (Laks & Alford, 2024; Thakrar & Rastegar, 2025).

The analgesic and euphoric effects of opioids are contingent upon their ability to cross the blood-brain barrier and access the central nervous system (Schaefer et al., 2017). Heroin, for example, is highly lipophilic, allowing it to rapidly enter the brain where it is hydrolyzed to morphine, which then produces its powerful pharmacological actions (Hosztafi, 2011; Krishnan, 2024; Blatman, 1974). The intense, pleasurable sensation or "rush" described by users is directly related to this rapid receptor activation (Hosztafi, 2011). Chronic administration of high doses of these agonists leads to profound neuroadaptations in the endogenous opioid system, which are central to the development of tolerance and physical dependence (Smith et al., 1988; Hosztafi, 2011).

### The Dopaminergic Reward Pathway

A common neurobiological substrate for all addictive substances, including opioids, is their ability to powerfully activate the mesocorticolimbic dopamine system (Ivlieva, 2011; Scuvée‐Moreau, 2013; Velásquez-Martínez & Ortíz, 2014). This circuit, often called the brain's reward pathway, originates in the ventral tegmental area (VTA) and projects to limbic structures, most notably the nucleus accumbens (NAc) (Tyler & Leggio, 2024; Baker et al., 2002). The release of dopamine in the NAc is a critical event that mediates feelings of pleasure and reinforcement, strengthening behaviors that lead to its release (Dhillon, 2013; Plaisance et al., 2024).

Opioids increase dopamine in the NAc not by direct action on dopamine neurons, but through a process of disinhibition (Corre, 1997; Tyler & Leggio, 2024). VTA dopamine neurons are tonically inhibited by local GABAergic interneurons. Opioids, by binding to MORs on these GABAergic interneurons, suppress their inhibitory activity. This "release of the brake" allows VTA dopamine neurons to fire more robustly, causing a surge of dopamine in the NAc (Corre, 1997; Tyler & Leggio, 2024). This powerful, drug-induced stimulation of the reward pathway is far more intense and prolonged than that produced by natural rewards, leading to a potent reinforcing effect that drives initial and repeated drug use (Scuvée‐Moreau, 2013; Roques, 2000). Over time, this repeated supraphysiological stimulation leads to neuroplastic changes that diminish the brain's response to natural rewards and create an incentive salience for the drug and its associated cues (Kalivas et al., 2003; Franken & Wiers, 2013).

### Other Interacting Neurotransmitter Systems

While the opioid and dopamine systems are central, OUD involves widespread dysregulation of other critical neurotransmitter systems.

**Glutamate:** As the brain's primary excitatory neurotransmitter, glutamate is fundamentally involved in the neuroplasticity, learning, and memory processes that consolidate addictive behaviors (Antonio & Alfredo, 2012; Tyler & Leggio, 2024). The N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor, is critically implicated in the development of opioid tolerance and opioid-induced hyperalgesia (OIH), a paradoxical state of heightened pain sensitivity (Trujillo, 2012; Tawfic et al., 2013; King et al., 2005). Chronic opioid exposure leads to an upregulation of NMDA receptor function, contributing to a state of neuronal hyperexcitability that manifests during withdrawal (Tyler & Leggio, 2024).

**GABA (γ-aminobutyric acid):** GABA is the brain's main inhibitory neurotransmitter and plays a crucial role in balancing neuronal excitability. As noted, the disinhibition of VTA dopamine neurons is a GABA-mediated process (Corre, 1997). Chronic opioid use leads to adaptations in the GABA system, and the hyperexcitability seen during withdrawal is partly a consequence of a rebound decrease in GABAergic tone (Antonio & Alfredo, 2012; Tyler & Leggio, 2024). Benzodiazepines, which are GABA-A receptor modulators, are frequently co-abused with opioids, and this combination significantly increases the risk of fatal respiratory depression (Limandri, 2018; Watson et al., 2020).

**Norepinephrine (Noradrenaline):** The noradrenergic system, with cell bodies originating in the locus coeruleus (LC), is a key mediator of arousal, vigilance, and the physiological stress response. Opioids acutely suppress the firing of LC neurons, contributing to their sedative effects (Pergolizzi et al., 2020). With chronic use, the LC system undergoes compensatory upregulation. During withdrawal, the abrupt removal of opioid inhibition leads to a massive rebound hyperactivity of LC neurons, producing many of the classic autonomic signs of withdrawal, such as sweating, tachycardia, piloerection, and feelings of anxiety and restlessness (Watson et al., 2020; Dunn et al., 2023).

**Serotonin:** The serotonin system is involved in regulating mood, sleep, appetite, and impulsivity (Marchesi et al., 2008). Dysregulation of serotonin is implicated in the high rates of comorbid depression and anxiety in individuals with OUD (Sullivan, 2018). There is evidence of complex interactions between the opioid and serotonin systems, with some opioids also affecting serotonin reuptake (Salinsky et al., 2023; Mitra, 2018). This interaction may contribute to both the mood-altering effects of opioids and some of their adverse effects, such as nausea (Smith et al., 2012).

### The Stress System and Negative Reinforcement

Modern theories of addiction emphasize a transition from drug use driven by positive reinforcement (seeking euphoria) to drug use driven by negative reinforcement (seeking relief from a negative emotional state) (Koob, 2020; Salaam, 2005). This negative state, termed "hyperkatifeia," is characterized by dysphoria, anxiety, irritability, and anhedonia, and is a hallmark of the withdrawal/negative affect stage of the addiction cycle (Koob, 2020; Heilig, 2023). The brain's stress systems, including the hypothalamic-pituitary-adrenal (HPA) axis and the extended amygdala, are profoundly dysregulated by chronic opioid use and become hyperactive during withdrawal (Sinha, 2018; Cadet, 2014). Key neuropeptides like corticotropin-releasing factor (CRF) and dynorphin are recruited within the extended amygdala, driving this negative affective state and promoting compulsive drug-seeking as a means to alleviate the distress (Koob, 2020; Massaly et al., 2016; Sirohi et al., 2012). Stress itself is a powerful trigger for relapse, acting through these sensitized neurocircuits to reinstate drug craving and seeking behavior long after detoxification (Stewart, 2003; Sinha, 2018).

## Genetic and Molecular Basis

The development of OUD is not an inevitable consequence of opioid exposure; it arises from a complex interplay between the drug, the environment, and an individual's biological vulnerability (Laks & Alford, 2024; Thyarappa Praveen et al., 2011). A substantial portion of this vulnerability is genetic, influencing everything from innate receptor sensitivity to the capacity for neuroplastic change.

### Heritability and Genetic Factors

Family, twin, and adoption studies provide strong evidence for a significant genetic component to the risk for substance use disorders, including OUD (DiMartini, 2007; Blum et al., 2022). Heritability estimates suggest that genetic factors account for a substantial portion of the variance in an individual's risk for developing addiction (DiMartini, 2007; Ivlieva, 2011). This genetic predisposition does not imply a single "addiction gene" but rather a polygenic architecture, where multiple genes, each with a small effect, contribute to overall vulnerability (Laks & Alford, 2024; Dolenc, 2015). A family history of substance abuse is a well-established risk factor (DiMartini, 2007; Zarkovic Palijan et al., 2007). Candidate genes under investigation are those involved in the opioid system (e.g., genes encoding opioid receptors), the dopamine system (e.g., genes for dopamine transporters and receptors), and systems involved in drug metabolism (e.g., cytochrome P450 enzymes) (Laks & Alford, 2024; Blum et al., 2022). Genetic variations can influence how an individual experiences the acute effects of opioids, the severity of withdrawal, and the propensity to transition to compulsive use (Thyarappa Praveen et al., 2011).

### Molecular and Cellular Mechanisms

Chronic opioid exposure triggers a cascade of molecular adaptations within neurons that collectively underlie the phenomena of tolerance, dependence, and addiction. These changes represent the brain's attempt to counteract the continuous drug-induced receptor stimulation and restore homeostasis—a process known as allostasis (Koob, 2020).

A classic molecular mechanism of opioid tolerance and dependence involves the adenylyl cyclase/cyclic adenosine monophosphate (cAMP) signal transduction pathway (Liu & JunHong, 2010; Smith et al., 1988). Opioid receptors are G-protein coupled receptors that, upon activation by an agonist like morphine, inhibit adenylyl cyclase, leading to a decrease in intracellular cAMP levels (Smith et al., 1988). With chronic opioid exposure, the cell compensates by upregulating this pathway (Antonio & Alfredo, 2012). When the opioid is withdrawn, the now-hyperactive cAMP system is no longer suppressed, leading to a massive overshoot in cAMP production. This cAMP surge is believed to drive many of the neuronal hyperexcitability signs characteristic of the opioid withdrawal syndrome (Liu & JunHong, 2010; Cepeda Pérez & Orellana, 2007).

Beyond the cAMP pathway, chronic opioid use leads to enduring changes in gene expression (Kalivas et al., 2003). These alterations are mediated by transcription factors such as the cAMP response element-binding protein (CREB), which is activated by the upregulated cAMP pathway (Antonio & Alfredo, 2012). Changes in gene expression lead to long-term structural and functional remodeling of neurons, a process known as neuroplasticity (Nidode et al., 2024; Mameli, 2009). These plastic changes are thought to be the substrate for the persistent vulnerability to relapse that characterizes addiction (Kalivas et al., 2003).

Furthermore, the field is increasingly recognizing the role of epigenetic mechanisms—such as DNA methylation and histone modification—in addiction (Cadet, 2014). Environmental factors like early life stress and repeated drug exposure can induce epigenetic changes that alter the expression of addiction-related genes without changing the DNA sequence itself (Sussman, 2025). These modifications can be long-lasting and may provide a molecular basis for how environmental experiences can confer a durable vulnerability to OUD (Cadet, 2014).

## Brain Structure and Function

The behavioral manifestations of OUD are the direct result of drug-induced dysfunction in a distributed network of brain circuits that govern reward, emotion, motivation, and executive function. The addiction cycle can be conceptualized as a three-stage process, with each stage being associated with a distinct neuroanatomical substrate (Tyler & Leggio, 2024; Koob, 2020).

### Key Neural Circuits in the Addiction Cycle

The **binge/intoxication stage** is primarily driven by the mesolimbic reward circuit, involving the VTA and NAc, as well as structures in the basal ganglia involved in habit formation (Tyler & Leggio, 2024; Koob, 2020). Acute opioid use activates this circuitry, producing reinforcing euphoria and promoting drug-taking behavior (Krishnan, 2024; Scuvée‐Moreau, 2013). With repeated use, control over drug-taking can shift from the NAc (involved in goal-directed behavior) to the dorsal striatum, which mediates stimulus-response habit learning, contributing to the automatic, compulsive nature of drug use (Piazza & Deroche‐Gamonet, 2013; Campos, 2017).

The **withdrawal/negative affect stage** is mediated by neuroadaptations in the extended amygdala and the habenula (Koob, 2020). As described earlier, hyperactivity of stress systems (e.g., CRF) and anti-reward systems (e.g., dynorphin) within the extended amygdala generates the intensely aversive emotional state of withdrawal (Koob, 2020; Massaly et al., 2016). This negative affective state becomes a powerful motivator for continued drug use through negative reinforcement—the individual takes the drug not for pleasure, but to escape dysphoria (Heilig, 2023; Ozdemir et al., 2023).

The **preoccupation/anticipation stage**, or craving, involves the prefrontal cortex (PFC), insular cortex, and hippocampus (Tyler & Leggio, 2024; Koob, 2020). The PFC is responsible for executive functions, including decision-making, impulse control, and assigning value to stimuli (Tyler & Leggio, 2024). In OUD, chronic opioid use impairs PFC function, leading to a reduced ability to inhibit drug-seeking impulses and a bias toward immediate drug reward over long-term negative consequences (Piazza & Deroche‐Gamonet, 2013). The insular cortex is involved in interoception and the conscious experience of craving, while the hippocampus encodes memories that link environmental cues with the drug experience, enabling these cues to trigger powerful cravings and relapse (Müller, 2013; Daley & Douaihy, 2019).

### Neuroimaging and Neuropathological Findings

Human neuroimaging studies provide evidence for the structural and functional brain abnormalities associated with OUD (Laks & Alford, 2024). Structural magnetic resonance imaging (MRI) studies have documented structural changes, including reduced gray matter volume in brain regions critical for executive control, such as the frontal cortex (Blackwood & Cadet, 2021; Krishnan, 2024). These structural deficits may be a consequence of long-term opioid use or a pre-existing vulnerability factor (Blackwood & Cadet, 2021). Cases of leukoencephalopathy, a demyelinating condition, have been reported, particularly following inhalation of heroin (Shprecher & Mehta, 2010).

Functional neuroimaging (fMRI) studies have demonstrated altered patterns of brain activity in individuals with OUD. For example, exposure to drug-related cues elicits robust activation in reward-related areas like the NAc and amygdala, as well as memory-related areas like the hippocampus, which correlates with subjective craving (Stewart et al., 2019; Daley & Douaihy, 2019). Concurrently, these individuals often show hypoactivation in prefrontal cortical regions responsible for cognitive control, reflecting an imbalance between hypersensitive reward-seeking drives and a compromised capacity for top-down regulation (Stewart et al., 2019; Tyler & Leggio, 2024).

The long-term cognitive consequences of these brain changes are significant. Individuals with OUD often exhibit deficits in attention, memory, and executive functions (Blackwood & Cadet, 2021; Sayeed et al., 2024; Lorea Conde et al., 2010). These cognitive impairments can persist even after prolonged abstinence and may interfere with treatment engagement and the ability to learn and apply relapse-prevention skills (Foo et al., 2012; Sayeed et al., 2024).

## Developmental Neurobiology

The trajectory of OUD is profoundly influenced by developmental factors, with adolescence representing a period of heightened vulnerability to the initiation of substance use and the rapid progression to addiction (Takahashi & Franklin, 1996; Sisk & Romeo, 2019).

### Adolescence as a Critical Period of Vulnerability

The adolescent brain undergoes significant maturational changes, particularly within the prefrontal cortex and the limbic reward systems (Sisk & Romeo, 2019). The PFC, responsible for executive functions like impulse control and long-term planning, is one of the last brain regions to fully mature, often not reaching full development until the mid-20s (Winters & Ingwalson, 2022). In contrast, the limbic reward pathways, which drive motivation and pleasure-seeking, are relatively mature and highly active during adolescence (Sisk & Romeo, 2019). This neurodevelopmental mismatch—a highly sensitive reward system coupled with an underdeveloped control system—creates a biological predisposition for risk-taking and novelty-seeking behaviors, including drug experimentation (Winters & Ingwalson, 2022; McArdle & Angom, 2012).

Exposure to opioids during this critical developmental window can have more profound and lasting effects than exposure in adulthood (Sisk & Romeo, 2019). Opioids can interfere with normal brain maturation processes, potentially leading to persistent alterations in neural circuitry that increase the long-term risk for addiction and other psychiatric disorders (Sisk & Romeo, 2019). Epidemiological data consistently show that an earlier age of onset of substance use is a strong predictor of developing a more severe and chronic substance use disorder later in life (Kamini, 2023; Upadhyaya, 2007; Girolamo et al., 2011).

### Impact of Early Life Stress and Trauma

The influence of developmental factors extends back to early childhood. Exposure to adverse childhood experiences (ACEs), such as physical, emotional, or sexual abuse, neglect, or significant family dysfunction, is a potent risk factor for the development of OUD and other substance use disorders in adolescence and adulthood (Merrick et al., 2019; Verma & Agrawal, 2021). There is a dose-response relationship, where a greater number of ACEs is associated with a higher risk of future substance use problems (Merrick et al., 2019).

From a neurobiological perspective, early life stress and trauma can permanently alter the development and function of the brain's stress-response and reward systems (Cadet, 2014; Sinha, 2018). Chronic stress during childhood can lead to long-term dysregulation of the HPA axis and sensitization of the neural circuits in the extended amygdala (Schepis et al., 2011). This can result in a heightened biological vulnerability to the effects of stress and a predisposition to using substances like opioids to self-medicate negative emotional states (Cadet, 2014; Khantzian, 1985). Thus, the neurobiological consequences of early adversity can set the stage for the initiation of drug use and the subsequent transition to addiction (Huhn & Ellis, 2022).

## Neuroplasticity, Compensatory Mechanisms, and Treatment Implications

The core clinical features of OUD—tolerance, dependence, withdrawal, craving, and hyperalgesia—are all manifestations of neuroplasticity, the brain's ability to change its structure and function in response to experience. Chronic opioid exposure drives a series of compensatory changes, or neuroadaptations, that attempt to counteract the drug's effects and maintain homeostasis (Nidode et al., 2024; Hayes & Lingford‐Hughes, 2023). While initially adaptive, these changes become maladaptive, forming the biological foundation of the disorder.

### Tolerance

Tolerance is defined as a diminished response to a drug after repeated administration, requiring an increased dose to achieve the same effect (Hansen, 2016; Leyde & Azari, 2020). It develops for many of opioid's effects, including analgesia and euphoria, but less so for others, like constipation (Smith et al., 1988; Lang & Patt, 1994). At the cellular level, tolerance involves mechanisms such as opioid receptor desensitization (uncoupling from G-proteins) and downregulation (a reduction in the number of receptors on the cell surface) (King et al., 2005). The upregulation of the cAMP pathway is also a key contributor to cellular tolerance (Liu & JunHong, 2010). It is critical for clinicians to differentiate true pharmacological tolerance from "pseudoaddiction," an iatrogenic syndrome where drug-seeking behaviors arise from the undertreatment of pain (Priya et al., 2021), and "pseudotolerance," where a need for increased dosage is due to disease progression or other factors rather than a change in opioid responsiveness (Pappagallo, 1998).

### Physical Dependence and Withdrawal

Physical dependence is the physiological state of adaptation to a substance, the absence of which produces a specific withdrawal syndrome (Hosztafi, 2011; Hansen, 2016). This state is a predictable consequence of chronic opioid therapy (Twycross, 1975). The opioid withdrawal syndrome is the clinical manifestation of the brain's homeostatic counter-adaptation (Isbell & Fraser, 1950; Koob, 2020). Systems that are chronically suppressed by opioids, such as the noradrenergic neurons of the locus coeruleus, become hyperactive upon drug cessation, leading to symptoms like anxiety, agitation, sweating, and tachycardia (Pergolizzi et al., 2020; Watson et al., 2020). This state of neuronal hyperexcitability is a hallmark of withdrawal and a major driver of continued drug use to avoid or alleviate these intensely aversive symptoms (Dunn et al., 2023; Salaam, 2005). The severity of the withdrawal syndrome can vary depending on the specific opioid, the duration of use, and individual factors (Sun, 1998).

### Psychological Dependence (Addiction) and Craving

Psychological dependence, the essence of addiction, is the compulsive, out-of-control drug use despite harmful consequences (Lee, 2024; Mahato et al., 2021). A central feature of this state is craving, an intense and often overwhelming urge to use the drug (Daley & Douaihy, 2019). Craving is not simply a response to withdrawal; it can be triggered long after physical withdrawal has subsided by exposure to drug-associated cues (people, places, things), stress, or re-exposure to the drug itself (Stewart, 2003). This phenomenon is driven by powerful, long-lasting associative memories stored in circuits involving the amygdala, hippocampus, and PFC (Müller, 2013; Franken & Wiers, 2013). These memories cause drug-related cues to acquire powerful incentive salience, capturing attention and motivating drug-seeking behavior, often in an automatic, implicit manner (Cepeda Pérez & Orellana, 2007; Kalivas, 2003).

### Opioid-Induced Hyperalgesia (OIH)

OIH is a paradoxical phenomenon where chronic opioid exposure results in a state of increased pain sensitivity (Bekhit, 2010; Sochacki, 2025). Patients may report that their pain is worsening despite escalating opioid doses, or they may develop new, diffuse pain in areas unrelated to their original pain condition (Mitra, 2018; Garuba et al., 2009). OIH is mechanistically distinct from tolerance, though the two can coexist and be difficult to differentiate clinically (Ballantyne & Shin, 2008; Tawfic et al., 2013). The leading hypotheses for OIH mechanisms involve the sensitization of pronociceptive pathways, including upregulation of the NMDA receptor system, increased activity of spinal dynorphins, and activation of descending pain facilitation pathways from the brainstem (King et al., 2005; Mitra, 2018; Daccache et al., 2017).

### Protracted Abstinence and Relapse Vulnerability

While the acute withdrawal syndrome typically subsides within days to weeks, a more subtle but persistent state of dysregulation, known as protracted abstinence, can last for months or even years (Dydyk et al., 2021; Dunn et al., 2023). This state is characterized by negative affect (dysphoria, anxiety, irritability), sleep disturbances, and heightened stress reactivity (Ozdemir et al., 2023; Heilig et al., 2010). These persistent neuroadaptations create an enduring vulnerability to relapse (Schuckit, 2016). As noted, relapse is typically precipitated by one of three main triggers: re-exposure to the drug, exposure to drug-associated cues, or exposure to stress (Stewart, 2003; Kalivas, 2003). Each of these triggers engages the sensitized and dysregulated neural circuits forged during the development of addiction, powerfully reactivating craving and compulsive drug-seeking behavior (Piazza & Deroche‐Gamonet, 2013).

## Treatment Mechanisms

Understanding the neurobiological underpinnings of OUD provides a clear rationale for the use of pharmacotherapies that target these specific mechanisms. Medication-assisted treatment (MAT) is the standard of care and is highly effective at reducing morbidity and mortality (Laks & Alford, 2024; Dydyk et al., 2021).

### Opioid Agonist Therapy (OAT)

OAT with methadone (a full MOR agonist) or buprenorphine (a partial MOR agonist) is the most effective treatment for OUD (Wolfgang et al., 2023; Kleber, 2007). These medications work by occupying and stabilizing MORs in the brain (Laks & Alford, 2024). This long-acting, stable receptor activation prevents the onset of withdrawal symptoms, reduces craving, and, due to cross-tolerance, blocks the euphoric effects of illicitly used short-acting opioids like heroin (Dydyk et al., 2021; Wolfgang et al., 2023). By normalizing the dysregulated opioid system, OAT allows individuals to disengage from compulsive drug-seeking and focus on psychosocial recovery (Rao & Kumar, 2008). Buprenorphine's partial agonism confers a "ceiling effect" on respiratory depression, offering a superior safety profile compared to full agonists (Laks & Alford, 2024; Komrowski & Sekhri, 2021).

### Opioid Antagonist Therapy

Naltrexone is an opioid antagonist that competitively blocks opioid receptors, primarily the MOR (Thakrar & Rastegar, 2025). By occupying the receptor without activating it, naltrexone prevents exogenous opioids from binding and producing their reinforcing effects (Laks & Alford, 2024). This blockade of euphoria can help extinguish the learned association between drug use and reward (Kleber, 2007). A significant barrier to naltrexone initiation is that patients must be fully detoxified from opioids to avoid precipitating a severe withdrawal syndrome (Laks & Alford, 2024).

### Overdose Reversal

Naloxone is a short-acting, high-affinity competitive opioid antagonist used to reverse opioid overdose (Dydyk et al., 2021). When administered, it rapidly displaces opioids from MORs, particularly in the brainstem respiratory centers, thereby reversing the life-threatening respiratory depression that is the primary cause of overdose death (Jones, 2016; Thakrar & Rastegar, 2025; Imtiaz et al., 2021). Its short duration of action means that repeated doses may be necessary, especially in cases of overdose with long-acting or highly potent opioids like fentanyl (Jones, 2016).

### Withdrawal Management

While detoxification alone is not considered an effective long-term treatment for OUD, managing the acute withdrawal syndrome is often a necessary first step (Kleber, 2007; Thompson & Weber, 2021). Medications targeting the noradrenergic hyperactivity of withdrawal, such as the α2-adrenergic agonists clonidine and lofexidine, are commonly used (Rao & Kumar, 2008; Pergolizzi et al., 2018). These agents act on autoreceptors in the locus coeruleus to decrease the surge in noradrenergic output, thereby alleviating many of the autonomic symptoms like sweating, chills, and gastrointestinal distress (Watson et al., 2020). Tapering doses of methadone or buprenorphine is also a highly effective method for managing withdrawal (Kleber, 2007; Thompson & Weber, 2021).

## Future Directions

While our understanding of the neurobiology of OUD has advanced significantly, many questions remain. The clinical presentation and course of OUD are remarkably heterogeneous, suggesting the existence of distinct biological subtypes that may respond differently to treatments. Future research must focus on identifying biomarkers—genetic, neuroimaging, or molecular—that can help parse this heterogeneity and guide personalized treatment approaches (Laks & Alford, 2024).

The development of novel therapeutic targets is another critical frontier. Research is expanding beyond the classic opioid and monoamine systems to explore the roles of neuroinflammation, the gut-brain axis, and other neuropeptide systems in the pathophysiology of addiction (Nidode et al., 2024; Tyler & Leggio, 2024). For example, agents that target stress systems (e.g., CRF antagonists) or glial cell modulators could represent new avenues for treatment (Heilig, 2023). Non-opioid adjunctive medications, such as cannabidiol, are also being explored for their potential to manage withdrawal and craving (Kudrich et al., 2021).

Longitudinal neuroimaging studies are needed to better understand the capacity for brain recovery during sustained abstinence and treatment (Stewart et al., 2019). Tracking the reversal of structural and functional deficits could provide objective markers of treatment success and help identify interventions that promote neural repair. Finally, translating the vast knowledge gained from preclinical animal models into effective human therapeutics remains a significant challenge, requiring innovative clinical trial designs and a stronger bridge between basic and clinical science (Fulton, 2014).

## Conclusion

Opioid Use Disorder is a devastating but treatable brain disorder founded upon a complex and deeply ingrained neurobiological substrate. It is not a moral failing but a disease of brain reward, motivation, memory, and control circuits (Franklin, 1995; Blum et al., 2022). The initial euphoric effects of opioids, mediated by the disinhibition of the mesolimbic dopamine pathway, powerfully reinforce drug-taking behavior (Corre, 1997; Tyler & Leggio, 2024). With chronic use, the brain undergoes a series of profound neuroadaptations in an attempt to maintain homeostasis. These allostatic changes, occurring within the opioid, dopamine, glutamate, noradrenergic, and stress systems, become maladaptive (Koob, 2020). They lead to the development of tolerance, a severe physical and affective withdrawal syndrome, and a state of incentive sensitization where drug-related cues trigger intense craving and compulsive drug-seeking (Piazza & Deroche‐Gamonet, 2013; Stewart, 2003). The impairment of prefrontal cortical function further compromises an individual's ability to exert cognitive control over these powerful, deeply learned drives (Tyler & Leggio, 2024).

This comprehensive biological understanding provides the scientific rationale for viewing OUD as a chronic medical illness (Shahrokh, 2017). It explains the compulsive nature of the disorder and the persistent vulnerability to relapse that can endure for years (Schuckit, 2016). It also validates the mechanisms of action for our most effective, life-saving pharmacotherapies, such as opioid agonist and antagonist treatments, which directly target the disordered neurocircuitry (Wolfgang et al., 2023). By continuing to unravel the intricate biological and neurological mechanisms of OUD, the scientific community can refine existing interventions and develop novel strategies to combat this public health crisis, ultimately offering greater hope for long-term recovery.

## References

1. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
2. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
3. Adler, A. C., Siegel, L., Wilder, R. T., Good, J., Reigart, J. R., Eckstein, O. S., Goldman, J. L., Hindman, D. E., Verhoef, P. A., Watt, K. M., Hsu, B., Huh, J. W., Lowrie, L., Ndely, S.-N., Satchell, M. A., Siegel, L., Srinivasan, V., Chatterjee, D., Diaz, C., ... Landrigan‐Ossar, M. (2025). Recognition and Management of Iatrogenically Induced Opioid Dependence and Withdrawal in Children: Clinical Report. PEDIATRICS. https://doi.org/10.1542/peds.2025-073169
4. Aghababaeian, H., & Ahvazi, L. A. (2018). Isn’t it Time to Use Opioid Drugs in Emergency Medical Services?. DOAJ (DOAJ: Directory of Open Access Journals).
5. Ahmed, H. U. (2023). Internet addiction: issues and concerns. Bangladesh Journal of Medicine. https://doi.org/10.3329/bjm.v34i20.66121
6. Akerman, S., Hammel, J. L., & Brunette, M. F. (2010). Dextromethorphan Abuse and Dependence in Adolescents. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2010.537515
7. Akram, A. S., Sarwar, R., Zafar, M. F., Umair, M., Ullah, I., & Nazir, A. (2023). First oral treatment zuranolone’s FDA approval and its impact on postpartum depression: a new hope – a correspondence. International Journal of Surgery Global Health. https://doi.org/10.1097/gh9.0000000000000345
8. Aksoy, A., & Ögel, K. (2003). Kendine zarar verme davranişi.
9. AlAbdullah, H., Al-Mulhim, A. A., & Albanna, A. (2023). Pediatric Phagophobia: A Systematic Review and a Case Report of Pharmacological Interventions. New Emirates Medical Journal. https://doi.org/10.2174/0250688204666230622100605
10. Albertson, T. E., Chenoweth, J., Colby, D., & Sutter, M. E. (2016). The Changing Drug Culture: Medical and Recreational Marijuana.. PubMed.
11. Albuquerque, A. C. D., Silva, J. R. D., & Silva, J. (2015). The “roundabout Man” Trapped in the “roundabout City” – a Case Report of a Severe Obsessive Compulsive Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)32056-3
12. Aldweik, A. N., Hussain, K. H., & Alhaj, H. (2023). Can Functional Visual Loss Occur in an Older Adult Patient With a History of Stroke: A Case Report. BJPsych Open. https://doi.org/10.1192/bjo.2023.335
13. Alghamdi, B., Zrari, M., Elahi, A. M. N., Alwagdani, M., Alghamdi, E. A. S., Moafa, H., Miran, S., Alamoudi, S., Alshahrani, K., Binnwejim, M., & jaafari, M. A. (2018). Substance abuse and its psychiatric effect on adolescence. International Journal of Community Medicine and Public Health. https://doi.org/10.18203/2394-6040.ijcmph20182450
14. Ali, A. A., Shaer, S. S. E., Gad, A. M., & Abu‐Elfotuh, K. (2017). [P1–606]: IMPACT OF PHYSICAL AND MENTAL ACTIVITIES VERSUS PROTEIN MALNUTRITION ASSOCIATED WITH SOCIAL ISOLATION DURING INDUCTION AND PROGRESSION OF ALZHEIMER's DISEASE IN RATS. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.622
15. Ali, M., Malathesh, B. C., Chatterjee, S. S., Das, S., & Prasad, S. (2022). Mania/Hypomania induced by quetiapine: A case report and review of literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100093
16. Alkan, A., Öztorun, H. S., Karcı, E., Ürün, Y., Tuncay, G., Yaşar, A., Çınar, E., Aras, S., Varlı, M., Utkan, G., Demirkazık, A., Akbulut, H., & Şenler, F. Ç. (2020). The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients. Journal of Oncological Sciences. https://doi.org/10.37047/jos.2019-71889
17. Alldredge, B. K., & Simon, R. P. (2020). Drugs That Can Precipitate Seizures. CRC Press eBooks. https://doi.org/10.1201/9781003066736-69
18. Alloy, L. B., & Abramson, L. Y. (2010). Cyclothymic Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0249
19. Altawili, A. A., Altawili, M. A., Alzarar, A. H., Abdulrahim, N., Alquraish, H. H., Alahmari, M. A., Basyouni, M. H., Almohaya, Y. A., Alhabshan, W. M. S., Alshahrani, A. M., Alamrad, J. F. A., Aljumaah, A. S., Alsalman, M. A., & Alhafith, A. A. (2024). Adverse Events of the Long-Term Use of Opioids for Chronic Non-cancer Pain: A Narrative Review. Cureus. https://doi.org/10.7759/cureus.51475
20. Altay, M. A. (2019). Atomoxetine Induced Obsessive-Compulsive Disorder. Hospital Practices and Research. https://doi.org/10.15171/hpr.2019.12
21. Altree, T. J., & Currow, D. C. (2024). The use of opioids in late‐stage <scp>COPD</scp>—Where are we now?. Respirology. https://doi.org/10.1111/resp.14839
22. Alzahrani, H., Alharazi, M., Alzahran, G., Alroudan, D., Marwi, A., AlJamea, J., Alsubie, M., Alqahtan, A., Alzaher, M., & Alahmadi, N. (2022). Relationship of Substance Abuse and Living Situation on Burn Survivors. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21208
23. Amihăesei, I. C., & Cojocaru, E. (2014). Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.. PubMed.
24. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
25. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
26. Amron, S. B., Kandasami, G., Lee, C., Guo, S. L., & Tan, H. (2025). Making sense of ICD-11 diagnostic criteria of compulsive sexual behavioural disorder. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024266
27. Amsterdam, J. V., Pierce, M., & Brink, W. V. D. (2023). Predictors and motives of polydrug use in opioid users. A narrative review. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000875
28. Anand, K., Willson, D. F., Berger, J., Harrison, R., Meert, K. L., Zimmerman, J. J., Carcillo, J. A., Newth, C. J. L., Prodhan, P., Dean, J. M., & Nicholson, C. (2010). Tolerance and Withdrawal From Prolonged Opioid Use in Critically Ill Children. PEDIATRICS. https://doi.org/10.1542/peds.2009-0489
29. Ancoli‐Israel, S. (2005). Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults.. PubMed.
30. Anghel, L., Boev, M., Stănescu, C., Caramfil, S. M., Luca, L., Mușat, C. L., & Ciubară, A. (2023). Depression in the Diabetic Patient. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/14.4/526
31. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
32. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
33. Aptikieva, L. (2020). PSYCHOLOGICAL VIOLENCE CONSEQUENCES FOR DIFFERENT AGE CATEGORIES. Vestnik Orenburgskogo gosudarstvennogo universiteta. https://doi.org/10.25198/1814-6457-224-6
34. Aquina, C. T., Marques‐Baptista, A., Bridgeman, P., & Merlin, M. A. (2009). OxyContin® Abuse and Overdose. Postgraduate Medicine. https://doi.org/10.3810/pgm.2009.03.1988
35. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
36. Aretouli, E., Malik, M., Widmann, C., Parker, A. M., Oh, E. S., & Vannorsdall, T. D. (2025). Cognitive and mental health outcomes in long covid. BMJ. https://doi.org/10.1136/bmj-2024-081349
37. Arias-Falcón, Y., Reyes-Castellano, A. J., & Pequeño-Rondón, M. M. (2020). Síndrome del niño maltratado. Revista electrónica "Dr. Zoilo E. Marinello Vidaurreta".
38. Arora, A., O'Neill, A., Crome, P., & Martin, F. C. (2014). Clinical Medicine and Substance Misuse. https://doi.org/10.1002/9781118430965.ch5
39. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
40. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
41. ARYANI, L. N. A., & MANIK, I. G. N. W. (2024). KOMORBIDITAS TRAUMA FISIK OKULI SINISTRA DAN GANGGUAN MENTAL PERILAKU AKIBAT ZAT MULTIPEL YANG MERUGIKAN PADA WARGA BINAAN LAPAS. HEALTHY Jurnal Inovasi Riset Ilmu Kesehatan. https://doi.org/10.51878/healthy.v3i1.2996
42. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
43. Auvin, S., Kechid, G., Jardri, R., Vallée, L., Delion, P., & Goëb, J.-L. (2008). Hearing Hallucinations in a 12-Year-Old Child. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v10n0411b
44. Avidan, M. S., & Evers, A. S. (2011). Review of Clinical Evidence for Persistent Cognitive Decline or Incident Dementia Attributable to Surgery or General Anesthesia. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-2011-101680
45. Awad, M., Burke, H., & Oakman, S. A. (2024). Kratom-Induced Psychiatric Decompensation and Paranoid Delusions. Cureus. https://doi.org/10.7759/cureus.54626
46. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
47. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
48. Baat, C. D. (2017). Medicaments and oral healthcare 4. Pharmacotherapy in (frail and care dependent) older people. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2017.05.16244
49. Bajabir, D., Albishri, A., Shaheen, H. A., Albalawi, A., Alshikhi, A., Alkhan, S., Almulhim, N., Alsaileek, Y., Alotaibi, M., Almuhanna, M., & Namar, R. A. (2022). Common Conditions Associated with Long Term Opioid Usage. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21215
50. Bajwa, S. J. S. (2012). Rare and Serious Side Effects in Chronic Pain after Opioids. Journal of Pain & Relief. https://doi.org/10.4172/2167-0846.1000106
51. Baker, A., & Dawe, S. (2005). Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment. Australian Psychologist. https://doi.org/10.1080/00050060500094654
52. Baker, D. L., Cornish, J. L., & Kalivas, P. W. (2002). Glutamate and Dopamine Interactions in the Motive Circuit. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_9
53. Baldessarini, R. J., Suppes, T., & Tondo, L. (1996). LITHIUM WITHDRAWAL IN BIPOLAR DISORDER. American Journal of Therapeutics. https://doi.org/10.1097/00045391-199607000-00004
54. Balhara, Y. S., Verma, R., & Mathur, S. (2011). Management of attention-deficit hyperactivity disorder. Journal of Pediatric Neurosciences. https://doi.org/10.4103/1817-1745.84400
55. Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of Opioids for Chronic Pain. Clinical Journal of Pain. https://doi.org/10.1097/ajp.0b013e31816b2f26
56. Bandelow, B., & Wedekind, D. (2015). Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.2497
57. Barkin, R. L., Barkin, S. J., Irving, G., & Gordon, A. (2011). Management of Chronic Noncancer Pain in Depressed Patients. Postgraduate Medicine. https://doi.org/10.3810/pgm.2011.09.2470
58. Barrio, P., Seeman, M. V., & González-Rodríguez, A. (2021). Alcohol and Psychosis: A Narrative Review of the Prevalence, Clinical Manifestations, and Management of Alcohol-related Psychotic Symptoms. Current Psychiatry Research and Reviews. https://doi.org/10.2174/2666082217666210602111739
59. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
60. Bartova, L., Dold, M., Volz, H. P., Seifritz, E., Möller, H., & Kasper, S. (2025). ANTIDEPRESSANT EFFECTS OF SILEXAN IN PATIENTS WITH PRIMARY ANXIETY SYNDROMES. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.065
61. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
62. Batista, M. E. D. S., Deuner, M. C., Nascimento, G. P. V. D., Silva, L. A. D. S., & Oliveira, G. O. B. D. (2025). BENZODIAZEPINES: IMMEDIATE BENEFITS, LONG TERM RISKS. https://doi.org/10.63330/aurumpub.009-003
63. Becker, W. C., Frank, J. W., Edmond, S. N., & Starrels, J. L. (2023). When harms outweigh benefits of long‐term opioid therapy for pain: Need for a new diagnostic entity, research and improved treatments. Addiction. https://doi.org/10.1111/add.16348
64. Bekhit, M. H. (2010). Opioid-Induced Hyperalgesia and Tolerance. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e3181ed83a0
65. Belt, A., Weisheit, R. A., Stalcup, S. A., & Galloway, G. P. (2013). Treating Incarcerated Juvenile Methamphetamine Abusers. Journal of Psychology Research. https://doi.org/10.17265/2159-5542/2013.08.004
66. Benton, T. D., Staab, J. P., & Evans, D. L. (2007). Medical Co-Morbidity in Depressive Disorders. Annals of Clinical Psychiatry. https://doi.org/10.1080/10401230701653542
67. Berde, C. B., & Nurko, S. (2008). Opioid Side Effects — Mechanism-Based Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejme0801783
68. Berry, M. S., & Dunn, K. E. (2024). Pain and withdrawal are common among patients receiving medications for opioid use disorder and associated with pain catastrophizing, negative affect, and poor sleep.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/pha0000723
69. Bersselaar, L. R. V. D., Hoeven, J. G. V. D., & Jong, B. D. (2020). Feeling Death, Being Alive: 4-Methylethcathinone/Pentedrone Addiction and 3-Methoxyphencyclidine Intoxication. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000214
70. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
71. Beutler, B. D., Shinozuka, K., Tabaac, B. J., Arenas, A., Cherian, K., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD). American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001726
72. Bhatt, A., & Gill, A. (2016). Opiate addiction - current trends and treatment options. International Journal of Research in Medical Sciences. https://doi.org/10.18203/2320-6012.ijrms20161911
73. Biali, M. E., & Besson, M. (2020). [Why using antidepressants in chronic pain ? Practical prescription recommendations].. PubMed.
74. Bibi, E. S. D. M. (2021). AN OVERVIEW OF POST WAR SOCIAL PROBLEMS IN SYRIA. Pakistan Journal of International Affairs. https://doi.org/10.52337/pjia.v2i2.63
75. Bidaki, R., Yassini, S. M., & Anari, P. Y. (2016). Bizarre Delusions Follow Dopaminergic Therapy in Parkinson Disease: Challenge in Diagnosis and Treatment.
76. Bjork, J. M., & Thomson, N. D. (2020). Stress and Substance Misuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190920197.003.0006
77. Black, D. W. (2007). Compulsive Buying Disorder: <i>A Review of the Evidence</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900020630
78. Blackwood, C. A., & Cadet, J. L. (2021). The molecular neurobiology and neuropathology of opioid use disorder. Current Research in Neurobiology. https://doi.org/10.1016/j.crneur.2021.100023
79. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
80. Blatman, S. (1974). Narcotic Poisoning of Children (1) Through Accidental Ingestion of Methadone and (2) <i>in utero</i>. PEDIATRICS. https://doi.org/10.1542/peds.54.3.329
81. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
82. Blinick, R., Chaya, N., Zalta, B., Haramati, L. B., & Shmukler, A. (2020). Cracking the Opium Den. Journal of Thoracic Imaging. https://doi.org/10.1097/rti.0000000000000488
83. Blum, K., Bowirrat, A., Baron, D., Badgaiyan, R. D., Thanos, P. K., Elman, I., Braverman, E. R., & Gold, M. S. (2022). Understanding that Addiction Is a Brain Disorder Offers Help and Hope. Health. https://doi.org/10.4236/health.2022.146050
84. Bolton, D., Hailu, T., & Porucznik, C. A. (2023). Resolution of stuttering during ketamine treatment: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-023-04158-8
85. Bordini, L., Riboldi, L., & Ferrario, M. (2013). [Psychotropic substances and driving].. PubMed.
86. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
87. Bousoño, M., Baca, E., Alvarez, E., Eguiluz, I., Martin, M., Roca, M., & Urretavizcaya, M. (2008). Complicaciones de la depresión a largo plazo. Actas Españolas de Psiquiatría.
88. Brahm, N. C., & Fast, G. A. (2009). Increased Sexual Aggression Following Ziprasidone Discontinuation in an Intellectually Disabled Adult Man. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.08l00722
89. Bril, S., Shoham, Y., & Marcus, J. S. (2011). The ‘Mystery’ of Opioid-Induced Diarrhea. Pain Research and Management. https://doi.org/10.1155/2011/309685
90. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
91. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
92. Broniarczyk-Czarniak, M., Sowińska, K., Białas, J., & Talarowska, M. (2019). Ciężka depresja z nasilonymi zaburzeniami funkcji poznawczych czy otępienie.
93. Bruch, S. (2013). Cultural concerns and issues in emergency psychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.041
94. Brüne, M. (2008). Substance Abuse and Substance Dependence. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199207688.003.0010
95. Brădeanu, A. V., Pascu, L. S., Ungurianu, S., Tutunaru, D., Rebegea, L., Terpan, M., & Ciubară, A. (2019). The Effect of Behaviour in Patients Who Are Hospitalized and Suffer from Alcohol Withdrawal. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s2/5
96. BS, R. A., & Veronica, A. S. (2016). Synthetic Cannabinoids and Dysphonia: A Case Report. Journal of General Practice. https://doi.org/10.4172/2329-9126.1000220
97. Buckley, P. (1998). Substance abuse in schizophrenia: a review.. PubMed.
98. Buckley, P. (2007). Dual Diagnosis of Substance Abuse and Severe Mental Illness: The Scope of the Problem. Journal of Dual Diagnosis. https://doi.org/10.1300/j374v03n02_07
99. Buga, S., Banerjee, C., Zachariah, F., & Freeman, B. (2017). Ambivalenţa chimică: prezentare de caz. Oncolog-Hematolog ro.
100. Buga, S., Banerjee, C., Zachariah, F., & Freeman, B. (2017). Chemical coping: a case study. Oncolog-Hematolog ro.
101. Bustos, W. P. V., & Vásquez, A. P. G. (2018). Intoxicación oral por benzodiacepinas. Reporte de caso y revisión bibliográfica.
102. Bögli, S. Y., Capone, C., Baumgartner, M. R., Quednow, B. B., Kræmer, T., Keller, E., & Binz, T. M. (2024). Delirium in Neurocritical Care: Uncovering Undisclosed Psychotropic Substance and Medication Use and Stress Exposure by Hair Analysis. Neurocritical Care. https://doi.org/10.1007/s12028-024-02052-9
103. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
104. Cabero, M. D. L. H., López, S. B., Borrego, N., Carrascal, I. O., Flores, L., & Rico, R. J. (2016). Severe behavioral disturbances in bipolar disorder: A case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1141
105. Cabrejo-Mendoza, H. J., & Albornoz-Muñoz, D. P. (2023). Trastorno de Acumulación: A propósito de un caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v86i1.4469
106. Cadet, J. L. (2014). Epigenetics of Stress, Addiction, and Resilience: Therapeutic Implications. Molecular Neurobiology. https://doi.org/10.1007/s12035-014-9040-y
107. Calami, A., & Dowdall, D. (2015). The challenge of opioid-induced hyperalgeisa..
108. Campana, R. (2017). The Basics of Addiction. MOJ Addiction Medicine & Therapy. https://doi.org/10.15406/mojamt.2017.03.00046
109. Campos, R. C. (2017). Striatum, Dopamine and Automatism in Cocaine Addiction and Relapse : Pharmacological and Behavioral Investigation.
110. Cantisani, T. A., Celani, M. G., Hankey, G. J., & Sandercock, P. (2012). An old drug for a common disease. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2012-304183
111. Cappa, M., Bizzarri, C., Vollono, C., Petroni, A., & Banni, S. (2010). Adrenoleukodystrophy. Endocrine development. https://doi.org/10.1159/000321236
112. Caraiane, A., Szalontay, A. S., Macovei, L. A., Romila, A., Indrei, L. L., Decusară, M., & Tarc, T. (2018). Oral-Facial Manifestations Caused by the Use of Psychotropic Medication in Psychiatric Patients. Revista de Chimie. https://doi.org/10.37358/rc.18.6.6374
113. Carnovale, C., Pellegrino, P., Perrone, V., Antoniazzi, S., Pozzi, M., Nisic, A., Clementi, E., & Radice, S. (2013). Neurological and psychiatric adverse events with prucalopride: case report and possible mechanisms. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.12087
114. Carr, B. I., Akkız, H., Guerra, V., Üsküdar, O., Kuran, S., Karaoğullarından, Ü., Tokmak, S., Ballı, T., Ülkü, A., Akçam, T., Delik, A., Benli, B. A., Doran, F., Yalçın, K., Altntaş, E., Özakyol, A., Yücesoy, M., Bahçeci, H. İ., Polat, K. Y., ... Tokat, Y. (2018). The patient burden of opioidinduced bowel dysfunction. Clinical Practice. https://doi.org/10.4172/clinical-practice.1000409
115. Cassano, G. B., Toni, C., Petracca, A., Deltito, J., Benkert, O., Curtis, G., Hippius, H., Maier, W., Shera, D., & Klerman, G. L. (1994). Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. European Neuropsychopharmacology. https://doi.org/10.1016/0924-977x(94)90314-x
116. Cata, J. P., Bugada, D., & Andrés, J. D. (2017). Opioid-less perioperative care. Minerva Anestesiologica. https://doi.org/10.23736/s0375-9393.16.11698-0
117. Catalano, G., Catalano, M. C., & Rodríguez, R. (1997). Dystonia Associated With Crack Cocaine Use. Southern Medical Journal. https://doi.org/10.1097/00007611-199710000-00017
118. Cesari, M., & Arosio, B. (2022). The use and abuse of prescribed medicines. Pathy's Principles and Practice of Geriatric Medicine. https://doi.org/10.1002/9781119484288.ch105
119. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
120. Chanen, A. M., & Thompson, K. (2016). Prescribing and borderline personality disorder. Australian Prescriber. https://doi.org/10.18773/austprescr.2016.019
121. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
122. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
123. Charlesworth, J., Ghosn, O., Hussain, N., Mahmoud, R., Goncalves, V., & Godbole, M. (2023). A case report of an unusual presentation of a patient with recurrent idiopathic catatonia. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100111
124. Chartrand, M. S. (2018). Awareness alert: adverse effects of hearing loss on mental and physical health. Journal of Otolaryngology-ENT Research. https://doi.org/10.15406/joentr.2018.10.00331
125. Chazan, S., Ekstein, M., Marouani, N., & Weinbroum, A. A. (2018). Ketamine for acute and subacute pain in opioid-tolerant patients. Journal of Opioid Management. https://doi.org/10.5055/jom.2008.0023
126. Chen, C., Liang, T., Ko, C., & Hsieh, H. (2022). The effectiveness of <scp>real‐time</scp> identification of medication ingestion in schizophrenic patients in Taiwan. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12637
127. Chen, Y.-S. (2012). Association between chronic insomnia and depression in elderly adults. Journal of the Chinese Medical Association. https://doi.org/10.1016/j.jcma.2012.04.001
128. Cheng, C., & Tsai, S. (2014). Persistent hiccups associated with switching from paliperidone to amisulpride. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12239
129. Cherian, K., Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001723
130. Chowdhury, T., Roy, P. D., & Chowdhury, H. I. (2021). Delusion in Parkinson’s disease: A Symptom or an Adverse Effect of Dopamine Agonist – A Case Report.
131. Chyćko, M., CZARNOTA, J., Cichoń, K., Krömer, A., Łapaj, M., Zapała, M., Środoń, A., Cholewa, M., Gawryś, A., & Wilk, J. (2023). The influence of bipolar disorder medication on sexual performance. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2023.42.01.004
132. Cienfuegos, J. J., Arriaga, M. Á. A., García, J. J., & Fernández, A. C. S. (2021). Propuesta de establecimiento de hábitos y rutinas que contemplen ejercicio y manejo del estrés para evitar el desgaste laboral durante el home office. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v5i3.583
133. Ciraulo, D. M., & Ciraulo, D. A. (2008). Benzodiazepines <i>Misuse, Abuse, and Dependence</i>. https://doi.org/10.1093/oso/9780195300550.003.0019
134. Coelho, C. M. M., Santos, G. X. C., Magano, S., Mota, D., Ferreira, S., Araújo, A. I., Cabaços, C., & Macedo, A. (2019). Treatment of Depersonalization-derealization Disorder With Transcranial Magnetic Stimulation. https://doi.org/10.26226/morressier.5d1a037457558b317a1404e8
135. Cohen, M. R., & Pickar, D. (1981). Pharmacological Challenges to the Endogenous Opioid System in Affective Illness. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198107000-00007
136. Cohen, R., Pereira, I., Garrido, M. M., Ferreira, B., & Sousa, M. D. C. (2023). Suicidal ideation in older people, a public health matter. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1786
137. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Managementul tratamentului tulburărilor cauzate de consumul de substanţe psihoactive. Psihiatru ro.
138. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Treatment management of psychoactive substance use disorders. Psihiatru ro. https://doi.org/10.26416/psih.59.4.2019.2604
139. Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2017). Prevalence of Marijuana Use Disorders in the United States.
140. Conaglen, H. M., & Conaglen, J. V. (2013). Drug-induced sexual dysfunction in men and women. Australian Prescriber. https://doi.org/10.18773/austprescr.2013.021
141. Conde, I. L., Fernández‐Montalvo, J., Ustárroz, J. T., González, N. L., & López‐Goñi, J. J. (2010). Rendimiento neuropsicológico en la adicción a la cocaína: una revisión crítica. Revista de Neurología. https://doi.org/10.33588/rn.5107.2010395
142. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
143. Corbett, A., Burns, A., & Ballard, C. (2014). Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. https://doi.org/10.1136/bmj.g6420
144. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
145. Correia‐Melo, F. S., Silva, S. S., Araújo-de-Freitas, L., & Quarantini, L. C. (2017). S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Brazilian Journal of Psychiatry. https://doi.org/10.1590/1516-4446-2016-2070
146. Correll, C. U., Kratochvil, C. J., & March, J. S. (2011). Developments in Pediatric Psychopharmacology. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11r07064
147. Cortese, S., & Risso, M. (2008). [Drug therapy of opioid withdrawal].. Vertex Revista Argentina de Psiquiatría.
148. Costa, S. C. D., Coutinho, B., & Novo, T. (2012). P-274 - Attention deficit hyperactivity disorder in adults: what is the approach?. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74441-3
149. Covington, H. E., & Miczek, K. A. (2010). Binge Drug Taking. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_15
150. Craske, M. G., Barlow, D. H., & Woodard, L. S. (2022). Facing Fear Out There. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780197608678.003.0005
151. Creado, S., Plante, D., & Casey, K. R. (2017). 1220 Veteran with Sleep Eating, Post-traumatic Stress Disorder and Severe Obstructive Sleep Apnea. SLEEP. https://doi.org/10.1093/sleepj/zsx052.010
152. Crocker, C. E., Carter, A., Emsley, J. G., Magee, K., Atkinson, P., & Tibbo, P. G. (2021). When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2021.640222
153. Cruz, M. P. (2011). Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia.. PubMed.
154. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
155. Culberson, J., & Ziska, M. (2008). Prescription drug misuse/abuse in the elderly.. PubMed.
156. Cunningham, S. (2019). Communicating Auditory Impairments Using Electroacoustic Composition. Electronic workshops in computing. https://doi.org/10.14236/ewic/eva2019.63
157. Cunnington, D., & Junge, M. (2016). Chronic insomnia: diagnosis and non-pharmacological management. BMJ. https://doi.org/10.1136/bmj.i5819
158. Daccache, G., Jeanne, M., & Fletcher, D. (2017). The Analgesia Nociception Index: Tailoring Opioid Administration. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000002145
159. Dadić-Hero, E., Ružić, K., Medved, P., Vorkapić, S. T., & Graovac, M. (2010). Antipsychotic side-effect - potential risk of patients rejecting their treatments.. PubMed.
160. Daley, D. C., & Douaihy, A. (2019). Effects of Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0004
161. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
162. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
163. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
164. Darke, S., Farrell, M., & Lappin, J. (2023). Overdose and suicide are different phenomena among opioid users that require different clinical management. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/00048674231159298
165. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
166. Dastidar, P. G. (2024). Quality Of Life and Functional Impairment in Adults withOcdReview Of Literature. African Journal of Biomedical Research. https://doi.org/10.53555/ajbr.v27i4s.4585
167. David, N. L., Factor, S. A., Tripathi, R., & Higginbotham, L. (2025). The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70114
168. Davies, D. (2023). Defining Alcoholism. Routledge eBooks. https://doi.org/10.4324/9781032616988-5
169. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
170. DeBattista, C., & DeBattista, K. (2010). Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects. Current Drug Safety. https://doi.org/10.2174/157488610791698325
171. Delanerolle, G., Shetty, S., Raymont, V., Hapangama, D. K., Haque, N., Shi, J. Q., Ayis, S., Shetty, A., & Phiri, P. (2021). None. LOJ Medical Sciences. https://doi.org/10.32474/lojms.5.5
172. Delgado, D. A. O., Rojas, M. C. O., & Olea, J. M. S. (2024). Episodio depresivo mayor de características catatónicas: Reporte de caso. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v5i1.75
173. Delgado, S., Mosquera, N., Herrera, J., Espín, P., & Aparicio, C. X. P. D. (2021). Daños neurológicos en adolescentes por consumo de cocaína. RECIMUNDO. https://doi.org/10.26820/recimundo/5.(suple1).oct.2021.125-130
174. Denbeaux, M., Camoni, S. A., Beroth, B., Chrisner, M., Loyer, C., & Taylor, P. W. (2012). Drug Abuse: An Exploration of the Government's Use of Mefloquine at Guantánamo. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.2002902
175. Denis, A., Vera, R., Recalde, A., Paats, A., & Esteche, A. (2017). Neuroleptic malignant-like síndrome. Revista Virtual de la Sociedad Paraguaya de Medicina Interna. https://doi.org/10.18004/rvspmi/2312-3893/2017.04(02)49-053
176. Deptola, S., Hemmann, B., Hemmelgarn, T., DiPaola, K., & Cortezzo, D. E. (2023). Propofol Sedation Washouts in Critically Ill Infants: A Case Series. The Journal of Pediatric Pharmacology and Therapeutics. https://doi.org/10.5863/1551-6776-28.4.354
177. Devlin, R. J., & Henry, J. A. (2008). Clinical review: Major consequences of illicit drug consumption. Critical Care. https://doi.org/10.1186/cc6166
178. Deyo, R. A., Korff, M. V., & Duhrkoop, D. (2015). Opioids for low back pain. BMJ. https://doi.org/10.1136/bmj.g6380
179. Dhanya, K., & Jithesh, M. (2024). Ayurvedic Management of Alcohol Use Disorder - A Case Series. AYUSHDHARA. https://doi.org/10.47070/ayushdhara.v10i6.1432
180. Dhillon, R. S. (2013). The Potential for Abuse: Addiction. Berkeley Scientific Journal. https://doi.org/10.5070/bs3181020649
181. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
182. DiFranza, J. R., Wellman, R. J., Mermelstein, R. J., Pbert, L., Klein, J. D., Sargent, J. D., Ahluwalia, J. S., Lando, H. A., Ossip, D. J., Wilson, K. M., Balk, S. J., Hipple, B., Tanski, S. E., Prokhorov, A. V., Best, D., & Winickoff, J. P. (2011). The Natural History and Diagnosis of Nicotine Addiction. Current Pediatric Reviews. https://doi.org/10.2174/157339611795735648
183. DiMartini, A. (2007). Natural history of alcohol use disorders in liver transplant patients. Liver Transplantation. https://doi.org/10.1002/lt.21342
184. Dimellis, D., & Konstantinos, N. (2015). Pharmacoepidemiology of Bipolar Disorder: A Review.
185. Diwan, P. V., & Dikshith, T. S. S. (2003). Nonmedical Use of Drugs. https://doi.org/10.1002/0471426075.ch14
186. Djamshidian, A., Pagnier, G., Frank, M. J., & Friedman, J. H. (2022). Impulse Control Disorders and the Dopamine Dysregulation Syndrome. Cambridge University Press eBooks. https://doi.org/10.1017/9781009039291.021
187. Dolenc, T. J. (2015). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214883.003.0044
188. Dolinak, D. (2017). Opioid Toxicity. Academic Forensic Pathology. https://doi.org/10.23907/2017.003
189. Donghi, A., Maidana, M., Vázquez, L. G., & Rodríguez, R. O. (2011). DIAGNÓSTICO DIFERENCIAL (NEUROSIS-PSICOSIS) DEL MODO DE TRATAMIENTO DEL DOLOR EN CONSUMIDORES DE PASTA BASE DE COCAÍNA (PACO). III Congreso Internacional de Investigación y Práctica Profesional en Psicología XVIII Jornadas de Investigación Séptimo Encuentro de Investigadores en Psicología del MERCOSUR.
190. Drew, D., & Marie, B. S. (2011). Pain in Critically Ill Patients With Substance Use Disorder or Long-term Opioid Use for Chronic Pain. AACN Advanced Critical Care. https://doi.org/10.1097/nci.0b013e318220c504
191. Drew, D., & Marie, B. S. (2011). Pain in Critically Ill Patients With Substance Use Disorder or Long-term Opioid Use for Chronic Pain. AACN Advanced Critical Care. https://doi.org/10.4037/nci.0b013e318220c504
192. Dukku, A. M. (2021). DRUG AND SUBSTANCE ABUSE AMONG YOUTH IN NIGERIA: TYPES, CAUSES AND IMPLICATIONS ON SOCIO-ECONOMIC DEVELOPMENT. INTERNATIONAL JOURNAL OF MANAGEMENT, SOCIAL SCIENCES, PEACE AND CONFLICT STUDIES.
193. Dunn, K. E., Bergeria, C. L., Ware, O. D., & Strain, E. C. (2023). The Opioid Withdrawal Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780197618431.013.8
194. Dydyk, A. M., Jain, N., & Gupta, M. (2021). Opioid Use Disorder.
195. d’Andrea, G., Marco, O. D., Semeraro, F. M., Carullo, R., Sensi, S. L., Pettorruso, M., & Martinotti, G. (2023). Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100188
196. Ea, N., Hw, B., & Oa, V. D. H. (2016). [Hypersexuality and other impulse control disorders in Parkinson's disease].. PubMed.
197. Eccleston, J., & Lucey, M. R. (2017). Substance use disorders before and after liver transplantation. Clinical Liver Disease. https://doi.org/10.1002/cld.657
198. Edwards, K. A., Merlin, J. S., Webster, F., Mackey, S., & Darnall, B. D. (2024). Breaking barriers: addressing opioid stigma in chronic pain and opioid use disorder. Pain. https://doi.org/10.1097/j.pain.0000000000003475
199. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
200. El-Hamady, M. M., El-Sayed, H., Bakry, S. E., & Youniss, M. (2020). Prevalence of Anxiety Disorders in Substance Related Disorders. Benha Journal of Applied Sciences. https://doi.org/10.21608/bjas.2020.137193
201. El-Sorogy, S. E., El-Hamady, M. M., Mohamed, A. S., & Dahroug, M. M. M. (2024). Sexual Disorders in Females with Bipolar Disorder. Benha Journal of Applied Sciences. https://doi.org/10.21608/bjas.2024.275914.1354
202. Elikowski, W., Małek‐Elikowska, M., Fertała, N., & Zawodna-Marszałek, M. (2021). Amiodarone-induced musical hallucinations.. PubMed.
203. Elliott, J., Opper, S. E., Agarwal, S., & Fibuch, E. E. (2012). Non-Analgesic Effects of Opioids: Opioids and the Endocrine System. Current Pharmaceutical Design. https://doi.org/10.2174/138161212803582414
204. Ertem, D. H., Maner, F., & Köksal, A. (2013). Text messaging as a new compulsive behavior in a patient with <scp>P</scp>arkinson's disease. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12015
205. Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2005.04.008
206. Espinosa‐Jovel, C., & Sobrino, F. (2017). Caffeine and headache: specific remarks. Neurología (English Edition). https://doi.org/10.1016/j.nrleng.2014.12.022
207. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
208. Ettensohn, M. F., Markey, S. M., & Levine, S. P. (2018). Considering Ketamine for Treatment of Comorbid Pain, Depression, and Substance Use Disorders. Psychiatric Annals. https://doi.org/10.3928/00485713-20180312-02
209. Evans, R. W. (2008). Treating migraine in the emergency department. BMJ. https://doi.org/10.1136/bmj.39560.696748.80
210. Facucho-Oliveira, J., Espada-Santos, P., Mesquita, B., Fraga, A., Albuquerque, M., Costa, M. D., Marinho, M., & Cintra, P. (2022). Aripiprazol and Hypersexuality: when partial is to much. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1865
211. Faeder, M., Hale, E., Hedayati, D., Israel, A., Moschenross, D., Peterson, M., Peterson, R., Piechowicz, M., Punzi, J., & Gopalan, P. (2023). Preventing and treating delirium in clinical settings for older adults. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231198462
212. Fagan, A., Kissack, J. C., & Augustin, B. (2008). Adverse Events Medication Treatment Costs in a Chronically, Severely Mentally Ill Forensics Population. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.2.2.6
213. Fahrudin, S., & Negara, P. D. (2024). Comparative Analysis of the Legal System in Indonesia and the Netherlands in the Sphere of Use of Psychotropic Substances. https://doi.org/10.31328/wglr.v1i2.598
214. Falk, A., Joseph, R., Smith, S., & Wilk, A. (2023). Mood and Anxiety Disorders: Major Depressive Disorder.. PubMed.
215. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
216. Fareed, A. M., Stout, S. C., Casarella, J., Vayalapalli, S., Cox, J., & Drexler, K. (2011). Illicit Opioid Intoxication: Diagnosis and Treatment. Substance Abuse Research and Treatment. https://doi.org/10.4137/sart.s7090
217. Farooq, N. S. M. U., Alex, A., & Matthews, R. (2016). Opioid Medications: Psychiatric Diagnosis. Journal of Addiction Research & Therapy.
218. Farrell, B., Hughes, L., Neutel, I., & Babcock, K. (2003). Facilitating the Process of Medication Re-evaluation and Withdrawal in the Long-Term Institutionalized Population: The Example of Cisapride. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v56i1.407
219. Farıdhosseını, F., & Zamani, A. (2012). A case report of somnambulism associated with olanzapine.. PubMed.
220. Fawale, B., Adebowale, A., Idowu, A. O., Balogun, S. A., Sanusi, A. A., & Komolafe, M. (2022). Tramadol-Induced Acute Seizures: A Report of Three Cases.. PubMed.
221. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
222. Ferigolo, M., Machado, A. G. D. S., Oliveira, N., & Barros, H. M. T. (2003). Ecstasy intoxication: the toxicological basis for treatment. Revista do Hospital das Clínicas. https://doi.org/10.1590/s0041-87812003000600008
223. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
224. Fipps, D. C., & Sinha, S. (2023). Substance Use Disorders and Sleep. Psychiatric Annals. https://doi.org/10.3928/00485713-20231019-01
225. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
226. Flores, C. (2010). FACTORES QUE INFLUYEN EN LA ADICCIÓN ADOLESCENTE. Contribuciones a las Ciencias Sociales.
227. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
228. Fountas, A., Chai, S. T., Kourkouti, C., & Karavitaki, N. (2018). MECHANISMS OF ENDOCRINOLOGY: Endocrinology of opioids. European Journal of Endocrinology. https://doi.org/10.1530/eje-18-0270
229. Franjić, S. (2023). Child Abuse and Neglect is a Serious Problem in Every Society. Deleted Journal. https://doi.org/10.33140/jre.01.01.03
230. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
231. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
232. Freidel, N., Kreuder, L., Rabinovitch, B. S., Chen, F. Y., Huang, R. S., & Lewis, E. (2024). Psychedelics, epilepsy, and seizures: a review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1326815
233. Friedrichsdorf, S. J. (2019). From Tramadol to Methadone. Clinical Journal of Pain. https://doi.org/10.1097/ajp.0000000000000704
234. Fulga, A., Neagu, A., Ciubară, A., Mușat, C. L., Neagu, M., & Fulga, I. (2019). Pro-active Drug Facilitated Sexual Assault Using Sedative - hypnotic Medication. Revista de Chimie. https://doi.org/10.37358/rc.19.11.7706
235. Fulga, A., Neagu, A., Ciubară, A., Mușat, C. L., Neagu, M., & Fulga, I. (2019). Pro-active Drug Facilitated Sexual Assault Using Sedative - hypnotic Medication. Revista de Chimie. https://doi.org/10.37358/rc.70.19.11.7706
236. Fulton, B. S. (2014). Conclusion. https://doi.org/10.1002/9781118943670.oth
237. Gable, M., & Depry, D. (2015). Psychosis Requiring Hospitalization in an Adult ADHD Patient on a Therapeutic Stimulant: A Case Report and Review of Treatment Alternatives. International Journal of Clinical Case Studies. https://doi.org/10.15344/2455-2356/2015/103
238. Galasko, D. (2019). Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429260353-28
239. Gallegos, A. P., & Aguilar, C. (2024). Síndrome de Abstinencia y Delirum Secundario al Uso de Opioides y Benzodiacepinas: Revisión Narrativa de la Literatura. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i1.10500
240. García, E., García, L. C., Villarroel, C. M., Revuelta, M. S., Cutanda, J. D., & Matsuura, J. (2021). Obsessive symptoms as first alert of psychosis: Two cases report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1625
241. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
242. Garuba, M., Mostek, D. E., & Burke, W. J. (2009). OPIOID‐INDUCED HYPERALGESIA IN A PATIENT WITH DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02209.x
243. Gautam, L., & Grela, A. (2020). Drink spiking and drug facilitated sexual assault.
244. Gentile, J. P. (2018). Aggression in Intellectual Disability. International Journal of Autism & Related Disabilities. https://doi.org/10.29011/2642-3227.000010
245. George, O., Ahmed, S. H., & Gilpin, N. W. (2022). Are we compulsively chasing rainbows?. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01419-w
246. Gevirtz, C., Vadivelu, N., & Kaye, A. D. (2014). Postoperative Pain Control in Drug Abusing Patients. Substance Abuse. https://doi.org/10.1007/978-1-4939-1951-2_30
247. Giasuddin, N. A., & Hossain, M. J. (2020). Understanding Obsessive Compulsive Disorder and Management Options. Faridpur Medical College Journal. https://doi.org/10.3329/fmcj.v15i1.49009
248. Giliberti, A., Frisina, A. M., Giustiniano, S., Carbonaro, Y., Roccella, M., & Nardello, R. (2025). Autism Spectrum Disorder and Epilepsy: Pathogenetic Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14072431
249. Giménez, V. M. M., Mazzei, L., Sanz, R., & Manucha, W. (2022). Cannabinoids as Potential Molecules for Addiction Disorders. Current Protein and Peptide Science. https://doi.org/10.2174/1389203723666220510121031
250. Girolamo, G. D., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2011). Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796011000746
251. Go, S., Won, Y., & Kang, J. H. (2022). Safe use of opioids. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2022.65.1.57
252. Goga, J. K., Seidel, L., Walters, J. K., Khushalani, S., & Kaplan, D. (2012). Acute Laryngeal Dystonia Associated With Aripiprazole. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e318272d468
253. Gold, D. G., & Fatemi, S. H. (2003). Phenelzine–Opiate–Induced Delirium Complicated by Phenelzine Withdrawal. Journal of Pharmacy Technology. https://doi.org/10.1177/875512250301900106
254. Gold, M. S. (2005). Dual Diagnosis. Journal of Dual Diagnosis. https://doi.org/10.1300/j374v01n01_02
255. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
256. Gomathy, S. B., Saini, A., Gupta, A., Vishnu, V. Y., Singh, M. B., Bhatia, R., Srivastava, M. P., Radhakrishnan, D. M., Srivastava, A. K., & Rajan, R. (2024). A rare yet treatable case of paroxysmal kinesigenic dyskinesia. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_28_23
257. Gombru, A., Brignell, G., & Donnelly, H. (2016). Sentencing for domestic violence.
258. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
259. González, T. M., & Martín, F. (2009). Pathological gambling and hypersexuality due to dopaminergic treatment in Parkinson' disease.. PubMed.
260. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
261. Gray, C., & McCormack, S. (2019). Yoga for Chronic Non-Malignant Pain Management: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines.
262. Greenberg, J., Penn, T. M., Doorley, J., Grunberg, V. A., Duarte, B. A., Fishbein, N. S., Bakhshaie, J., & Vranceanu, A. (2022). Pain catastrophizing, pain anxiety, and substance use among Black individuals with chronic pain who use opioids.. Psychology of Addictive Behaviors. https://doi.org/10.1037/adb0000881
263. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
264. Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S., Nutt, D., Okasha, A., Swinson, R. P., & Zohar, J. (2003). WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults. CNS Spectrums. https://doi.org/10.1017/s1092852900006908
265. Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Okasha, A., Zohar, J., Allgulander, C., Cassano, G. B., Pollack, M. S., & Ameringen, M. V. (2003). Recommendations for the Long-Term Treatment of Anxiety Disorders.
266. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Substance abuse disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.016
267. Grimby, G., & Jönsson, A.-L. T. (1994). Disability in Poliomyelitis Sequelae. Physical Therapy. https://doi.org/10.1093/ptj/74.5.415
268. Grory, S. Y.-M., & Potenza, M. N. (2020). Debates Regarding the Classification, Categorization, and Conceptualization of Problematic Internet Use and Video Gaming. https://doi.org/10.1093/oxfordhb/9780190218058.013.12
269. Gupta, D., & O’Hara, C. (2019). Aripiprazole Toxicity With a Biphasic Course of Somnolence. Pediatric Emergency Care. https://doi.org/10.1097/pec.0000000000001889
270. Gupta, J. K. (2020). Bipolar Disorder: A Major Setback in Substance Abuse. Indian Journal of Forensic Medicine & Toxicology. https://doi.org/10.37506/ijfmt.v14i3.10476
271. Gupta, R., Singh, A. P., Mittal, A., & Chaturvedi, S. K. (2024). "FROM BOOST TO BREAKDOWN "PERFORMANCE ENHANCEMENT AND THE DARK SIDE OF MEPHENTERMINE ADDICTION” A CASE SERIES. Global Journal For Research Analysis. https://doi.org/10.36106/gjra/0506138
272. Guszkowska, M. (2013). [Exercise dependence--symptoms and mechanisms].. PubMed.
273. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
274. Güngörmüş, Z., & Özgüç, S. (2025). Psychosocial problems observed in older adults after disaster. Psychogeriatrics. https://doi.org/10.1111/psyg.70001
275. Hachey, L. M., Gregg, J. A., Pavlik-Maus, T. L., & Jones, J. S. (2017). Health implications and management of women with opioid use disorder. Journal of Nursing Education and Practice. https://doi.org/10.5430/jnep.v7n8p57
276. Hadi, I., Wijayati, F., Usman, R. D., & Rosyanti, L. (2017). Major Depressive Disorder: A Mini Review. Health Information Jurnal Penelitian. https://doi.org/10.36990/hijp.v9i1.102
277. Hall, S. W. (2011). Idiopathic Environmental Intolerances. SpringerReference. https://doi.org/10.1007/springerreference_44303
278. Halma, M., Marik, P. E., Saleeby, Y. M., & Tuszyński, J. A. (2024). Integrative Chronic Pain Management: A Narrative Review. https://doi.org/10.20944/preprints202404.0471.v1
279. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
280. Hamza, S., Heba, G., & Am, N. (2019). Relationship between Sleep Disturbance and Polypharmacy among Hospitalized Elderly. Egyptian Journal of Geriatrics and Gerontology. https://doi.org/10.21608/ejgg.2019.139022
281. Hansen, J. (2016). Basics of Opioid Pharmacology.. PubMed.
282. Hansen, L., Nausheen, B., Hart, D., & Kingdon, D. (2013). Movement disorders in patients with schizophrenia and a history of substance abuse. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.2305
283. Harding, S. (2005). Continuing Professional Development Managing delirium in older people.
284. Harris, B., & Ferguson, K. (2023). Anesthetic Implications of Addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197584521.003.0041
285. Harwell, M. (2019). Working Through the Unconscious Assumption of Neglect. Psychoanalytic Inquiry. https://doi.org/10.1080/07351690.2019.1623623
286. Hatzigiakoumis, D. S., Martinotti, G., Giannantonio, M. D., & Janiri, L. (2011). Anhedonia and Substance Dependence: Clinical Correlates and Treatment Options. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2011.00010
287. Hayes, A., & Lingford‐Hughes, A. (2023). Drug Use, Addiction, Tolerance, Withdrawal and Relapse. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.058
288. Hd, K. (1985). Brief effective treatment strategies: pharmacological therapy for opiate addicts.. PubMed.
289. Hegde, D., Raj, B. N., Manamohan, N., Huded, C., & Pradeep, J. (2017). A Rare Case of Complicated Opioid Withdrawal in Delirium Without Convulsions. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.203109
290. Heilig, M. (2023). Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. Journal of Internal Medicine. https://doi.org/10.1111/joim.13636
291. Heilig, M., Egli, M., Crabbe, J. C., & Becker, H. C. (2010). Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2009.00194.x
292. Henegan, P., Koczara, J., Bluhm, R., & Cabrera, L. Y. (2024). Public Perceptions of Treating Opioid Use Disorder with Deep Brain Stimulation: A Comment Analysis Study (Preprint). Online Journal of Public Health Informatics. https://doi.org/10.2196/49924
293. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
294. Henning, A., Kurtom, M., & Espiridion, E. D. (2019). A Case Study of Acute Stimulant-induced Psychosis. Cureus. https://doi.org/10.7759/cureus.4126
295. Herndon, C. M., & Zimmerman, E. E. (2008). High-Dose Propofol Drip for Palliative Sedation: A Case Report. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909108319268
296. Herndon, C. M., Kalauokalani, D. A., Cunningham, A. J., Jackson, K. C., & Dunteman, E. (2003). Anticipating and treating opioidassociated adverse effects. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2.3.305
297. Hernández, A. R., Maria, A. M. D., Tarrés, A. A., García-Cascon, A. C., & Birba, J. V. (2018). Hiperalgesia inducida por opiáceos en un paciente con dolor crónico. Dolor: Investigación, clínica & terapéutica.
298. Hesapçıoğlu, S. T., Bilgier, S., & Kandil, S. (2013). ERGENLİKTE TEKRARLAYICI SUÇ İŞLEME, ALPRAZOLAM VE DİĞER MADDE BAĞIMLILIKLARI BİRLİKTELİĞİ. DergiPark (Istanbul University). https://doi.org/10.17343/sdutfd.30699
299. Heylens, G., Roosens, E., Mulier, J. P., & Fruyt, J. D. (2017). [The use of dexmedetomidine in extreme agitation].. PubMed.
300. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
301. Hoell, I., & Havemann‐Reinecke, U. (2011). [Pregnant opioid addicted patients and additional drug intake. Part I. Toxic effects and therapeutic consequences].. PubMed.
302. Hoell, I., Amanzada, A., Degner, D., & Havemann‐Reinecke, U. (2011). [Pregnant opioid addicted patients and additional drug intake. Part II: Comorbidity and their therapy].. PubMed.
303. Hogarth, L. (2020). Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-0600-8
304. Hope, C., & Rangel, N. A. (2024). 1221 Multiple Sleep Latency Testing in Patients with Comorbid Psychiatric Conditions: A Case Report. SLEEP. https://doi.org/10.1093/sleep/zsae067.01221
305. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
306. Huang, D., & Lukas, R. V. (2021). Complete Bilateral Hippocampal Diffusion Restriction and Reversible Amnesia Following Opiate, Cocaine, and Benzodiazepine Abuse. Cureus. https://doi.org/10.7759/cureus.12651
307. Huhn, A. S., & Ellis, J. D. (2022). Commentary on Zolopa <i>et al</i> .: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults. Addiction. https://doi.org/10.1111/add.15877
308. Huhn, A. S., & Finan, P. H. (2021). Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/pha0000477
309. Hyun, M. S. (1998). Dual Diagnosis. Journal of Korean Academy of Psychiatric and Mental Health Nursing. https://doi.org/10.12934/jkpmhn.1998.7.1.95
310. Ibáñez, C., Benavides, D., & Valle, D. (2019). Síndrome de hiperémesis por cannabinoides: caso clínico. Revista Hospital Clínico Universidad de Chile. https://doi.org/10.5354/2735-7996.2019.70048
311. Iff, S., Gähwiler, R., Butzke, I., Quednow, B. B., & Claussen, M. C. (2022). Recognizing IPED Use in Clinical Practice. Praxis. https://doi.org/10.1024/1661-8157/a003874
312. Iff, S., Gähwiler, R., Butzke, I., Quednow, B. B., & Claussen, M. C. (2022). Somatische Folgen des IPED-Gebrauchs früh in der Hausarztpraxis erkennen. Praxis. https://doi.org/10.1024/1661-8157/a003846
313. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
314. Imtiaz, M., Bandoian, C. V., & Santoro, T. J. (2021). Hypoxia driven opioid targeted automated device for overdose rescue. Scientific Reports. https://doi.org/10.1038/s41598-021-04094-x
315. Incze, M. (2019). I’m Worried About Depression—What Should I Know?. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.0637
316. Insel, T. R., Zahn, T. P., & Murphy, D. L. (2019). Obsessive-Compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203728215-40
317. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews.
318. Isbell, H., & Fraser, H. F. (1950). ADDICTION TO ANALGESICS AND BARBITURATES. Pharmacological Reviews. https://doi.org/10.1016/s0031-6997(25)07083-8
319. Ishii, N., Terao, T., Araki, Y., & Hatano, K. (2013). Repeated seizures in an elderly patient with alcohol dependence and mild cognitive impairment. BMJ Case Reports. https://doi.org/10.1136/bcr-2013-201575
320. Ivada, P. F., Ardani, I. G. A. I., Lesmana, C. B. J., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Fithriyah, I. (2022). Quality of life of pediatric patients experiencing organic depressive disorder with Juvenile Idiopathic Arthritis. International journal of health & medical sciences. https://doi.org/10.21744/ijhms.v5n4.1994
321. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
322. Ivy, J. W., Payne, J. L., & Neef, N. A. (2018). Increasing across-session variability of leisure activity selection for children with autism.. Behavior Analysis Research and Practice. https://doi.org/10.1037/bar0000132
323. İVECEN, B., & Gökdemir, Ö. (2022). Methamphetamine Addiction. DAHUDER Medical Journal. https://doi.org/10.56016/dahudermj.1184367
324. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
325. Jadhav, J., & Mankhair, S. (2023). Extrapyramidal syndrome - anaesthetist’s challenge: A case report. Medical Science. https://doi.org/10.54905/disssi/v27i138/e325ms3142
326. Jahan, A. R., & Burgess, D. M. (2021). Substance Use Disorder. StatPearls.
327. Jang, W. I., Kim, Y. S., Kim, D. W., & Lee, B. D. (2010). A Case of Bilateral Sudden Sensorineural Hearing Loss Occurring after Taking the Aspirin. Journal of Clinical Otolaryngology Head and Neck Surgery. https://doi.org/10.35420/jcohns.2010.21.1.67
328. Janiani, A., Ali, T., Garg, G., Chaudhury, S., Javedekar, A., & Singh, A. (2024). Alcohol-induced psychotic disorder with hallucinations (alcoholic hallucinosis): A case series. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_310_23
329. Jaya, M. A., & Syahrir, A. K. (2024). Psychodynamic Features of Depressed Patients with Dependent Personality Disorder and Hypokalemia: a Case Report. Action Research Literate. https://doi.org/10.46799/arl.v8i9.1901
330. Jehanzeb, S., & Javaid, A. (2025). The Life-Changing Diagnosis in a Patient With Treatment-Resistant Depression, From Darkness to Light and Healing. BJPsych Open. https://doi.org/10.1192/bjo.2025.10735
331. Jevtovic, J., Jovanović, J., Grujicic, M. V. –., & Vujcic, J. (2021). OCCUPATIONAL STRESS IN COMPUTER OPERATORS. Knowledge International Journal.
332. Jiménez, C., & Belén, M. (2019). Terapia de aceptación y compromiso grupal aplicada a pacientes adictos a los opioides con el manejo de los síntomas de abstinencia junto con la terapia farmacológica para evitar recaídas a futuro.
333. Johnson, J., & Buisman‐Pijlman, F. (2016). Adversity impacting on oxytocin and behaviour: timing matters. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000269
334. Jones, A. L. (2016). Management of opioid poisoning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199600830.003.0319
335. Jonge, M. E. A.-D., Portier, C., & Franssen, E. J. F. (2007). [Automutilation after consumption of hallucinogenic mushrooms].. PubMed.
336. Jordan, L. R. (2024). Complex emotional needs, overcontrol and death by suicide in older adults. FPOP Bulletin Psychology of Older People. https://doi.org/10.53841/bpsfpop.2024.1.166.33
337. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
338. Kaggwa, M. M., Nkola, R., Najjuka, S. M., Bongomin, F., Ashaba, S., & Mamun, M. A. (2021). Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System. Risk Management and Healthcare Policy. https://doi.org/10.2147/rmhp.s314451
339. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
340. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
341. Kallan, F. M., Siya, A., Kolenchery, J. J., D'silva, V. R., Nagdive, A., & Sethi, S. (2021). Seizures Presenting as ADHD: A Case Report. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i60b35017
342. Kamini (2023). Drug Addiction among Adolescents: An Analysis in Indian Context. RESEARCH HUB International Multidisciplinary Research Journal. https://doi.org/10.53573/rhimrj.2023.v10n02.002
343. Kanayama, G., Brower, K. J., Wood, R. I., Hudson, J. I., & Pope, H. G. (2009). Anabolic–androgenic steroid dependence: an emerging disorder. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02734.x
344. Karaş, H., & Kaşer, M. (2019). Use of Modafinil in Co-existing Major Depression and Erectile Dysfunction: A Case Report. Turkish Journal of Psychiatry. https://doi.org/10.5080/u23407
345. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
346. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
347. Kathula, P. (2020). Symptoms and Treatment of Depressive Disorders.
348. Katzman, M. A. (2021). The Diagnosis of Major Depressive Disorder is based on the Person's Reported Experiences and a Mental Status Examination. Journal of Aging and Geriatric Medicine.
349. Kaye, S. (2012). COMPULSIVE USE OF DOPAMINE REPLACEMENT THERAPY AMONG PARKINSON'S DISEASE PATIENTS: IF IT LOOKS LIKE A DUCK, SWIMS LIKE A DUCK AND QUACKS LIKE A DUCK . . .. Addiction. https://doi.org/10.1111/j.1360-0443.2011.03679.x
350. Keller, M. B., & Berndt, E. R. (2002). Depression treatment: a lifelong commitment?. PubMed.
351. Kelly, S., L.H., E., & Tr, D. (2012). Drugs in Development for Opioid-Induced Constipation. InTech eBooks. https://doi.org/10.5772/30377
352. Kempster, P., Williams, D. R., Selikhova, M., Holton, J., Révész, T., & Lees, A. J. (2007). Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain. https://doi.org/10.1093/brain/awm142
353. Kendrick, K. (2005). ORIGINAL ARTICLES Prolonged Paralysis Related to Mivacurium: A Case Study.
354. Kennedy, D. B., & Savard, D. M. (2017). Delayed In-Custody Death Involving Excited Delirium. Journal of Correctional Health Care. https://doi.org/10.1177/1078345817726085
355. Kern, A., Akerman, S., & Nordstrom, B. R. (2013). Opiate Dependence in Schizophrenia: Case Presentation and Literature Review. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2013.867199
356. Khan, A., Seth, N. H., & Sharath, H. V. (2024). Physical Rehabilitation Crucial in Motor Axonal Neuropathy Following Organophosphorus Poisoning: A Case Study. Cureus. https://doi.org/10.7759/cureus.54145
357. Khandelwal, S., & Desai, M. (2024). Prevalence of Fatigue Among Female Academicians. International Journal of Health Sciences and Research. https://doi.org/10.52403/ijhsr.20240324
358. Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry. https://doi.org/10.1176/ajp.142.11.1259
359. Kim, E. K. E., & Beckmann, D. (2021). An adolescent with binge drinking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0027
360. Kim, G. S., Nunez, T., & Vargas, E. (2021). Omeprazole-induced Visual Hallucinations: A Case Report. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000575
361. Kim, H., Park, C. I., Kim, H. W., Kang, J. I., & Kim, S. J. (2019). INFLUENCE OF DOPAMINE-RELATED GENES ON PROBLEMATIC DRINKINGS, IMPULSIVITY AND AGGRESSION IN KOREAN MALE PATIENTS WITH ALCOHOL USE DISORDER. https://doi.org/10.26226/morressier.5d1a037057558b317a14008c
362. Kim, W. M. (2013). Tramadol Induced Paradoxical Hyperalgesia. Pain Physician. https://doi.org/10.36076/ppj.2013/16/41
363. King, T., Ossipov, M. H., Vanderah, T. W., Porreca, F., & Lai, J. (2005). Is Paradoxical Pain Induced by Sustained Opioid Exposure an Underlying Mechanism of Opioid Antinociceptive Tolerance?. Neurosignals. https://doi.org/10.1159/000087658
364. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
365. Kirkby, K. C. (2007). Recognising and Responding to Candidates' Health Needs. ACER Press eBooks.
366. Kitching, D. (2015). Depression in dementia. Australian Prescriber. https://doi.org/10.18773/austprescr.2015.071
367. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2007.9.2/hkleber
368. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
369. Knapen, J., Vancampfort, D., Schoubs, B., Probst, M.-T., Sienaert, P., Haake, P., Peuskens, J., & Pieters, G. (2009). Exercise for the Treatment of Depression. The Open Complementary Medicine Journal. https://doi.org/10.2174/1876391x00901010078
370. Knight, E., & McIntyre, A. (2012). Pharmacy medications and driving: delivering key information to ageing drivers.
371. Knotnerus-Janssen, D. G. A. (2021). Psychotropic medication use in the Armed Forces: prescription patterns and treatment after trauma. https://doi.org/10.33540/923
372. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
373. Ko, J., & Kang, S. (2024). Case series of pyridoxine-induced neuropathy. Journal of Medicine and Life Science. https://doi.org/10.22730/jmls.2024.21.1.11
374. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
375. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
376. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
377. Komrowski, M. D., & Sekhri, N. (2021). A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain. Journal of Opioid Management. https://doi.org/10.5055/jom.2021.0641
378. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
379. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
380. Koob, G. F., Kandel, D. B., & Volkow, N. D. (2008). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9780470515167.ch22
381. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
382. Kovich, H., Kim, W., & Quaste, A. M. (2023). Pharmacologic Treatment of Depression.. PubMed.
383. Kowal, L., Mee, J. J., Nadkarni, S., Kalff, S., & Kozminsky, M. (2003). Acute esotropia in heroin withdrawal: a case series.. PubMed.
384. Koçak, Ö., & Koçak, S. (2023). Underrated Diagnosis: Prenatal Depression. Kafkas Journal of Medical Sciences. https://doi.org/10.5505/kjms.2023.21033
385. Krishnan, J. (2024). Heroin and its Effects on the Brain. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010003
386. Krishnan, J. (2024). MDMA (3,4-methylenedioxy-methamphetamine). BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010004
387. Krivoschekov, S. G. (2011). [Psychophysiology of sports addiction (exercises addiction)].. PubMed.
388. Kudrich, C., Hurd, Y. L., Salsitz, E. A., & Wang, A. (2021). Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2021.0089
389. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
390. Kumari, D., & Kumar, P. (2023). Psychosocial Functioning of Females with Chronic Anxiety Disorder. Journal of Psychosocial Well-being. https://doi.org/10.55242/jpsw.2023.4107
391. Kuntz, A., Karyoti, M., & Gothuey, I. (2019). [Adolescents and young adults with substance abuse and comorbid psychiatric disorders : which treatment ?]. PubMed.
392. Kwoun, Y.-J., Yoonjung, C., Oh, J., Park, K.-D., & Choi, K. (2003). Myeloneuropathy Following Chronic Abuse of Nitrous Oxide. Journal of the Korean Neurological Association.
393. Lahiri, D., Lima, B. S., Roncero, C., Stokes, K. A., Panda, S. S., & Chertkow, H. (2024). Psychotropic Polypharmacy Leading to Reversible Dementia: A Case Report. Cognitive and Behavioral Neurology. https://doi.org/10.1097/wnn.0000000000000380
394. Laks, J., & Alford, D. P. (2024). Treatment of opioid use disorder in patients with liver disease. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000207
395. Lamboglia, A. L. C., Rossi, A., Yanes, F. B., & Larraz, G. A. G. (2024). Secuelas neurológicas tardías en la intoxicación por monóxido de carbono. Reporte de un caso pediátrico.. ARS MEDICA Revista de Ciencias Médicas. https://doi.org/10.11565/arsmed.v49i2.2023
396. Lambrey, S., Quilici, G., Bonnefoy, C., Rosier, A., & Guillin, O. (2009). Clozapine as an Antiagressive Agent in an Adolescent with Autism. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)71243-x
397. Lang, S. S., & Patt, R. B. (1994). Understanding The Weak Opioids. https://doi.org/10.1093/oso/9780195084184.003.0006
398. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E., & Nutt, D. (2009). Chapter 13 Specific clinical situations. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0013
399. Law, F., Praveen, K. T., O’Shea, J., & Melichar, J. (2011). Opioid dependence.. PubMed.
400. Leconte, C. E., Ng, J. W., Manzardo, A. M., & Douglass, M. M. (2023). A Pediatric Patient with Severe Obstructive Sleep Apnea and Comorbid Depression and Substance Abuse. Case Reports in Psychiatry. https://doi.org/10.1155/2023/9985503
401. Lee, C., Wanson, A., Frangou, S., Chong, D., & Halpape, K. (2021). Opioid toxicity due to CNS depressant polypharmacy: A case report. Mental Health Clinician. https://doi.org/10.9740/mhc.2021.03.070
402. Lee, H., Kim, J., Lee, H.-S., Jo, Y.-H., Ko, J.-A., In, S., & Lee, J.-B. (2023). MS Fragmentation of ALD-52 with GC-MS and LC-QTOF. Korean Journal of Forensic Science. https://doi.org/10.53051/ksfs.2023.24.1.2
403. Lee, M. S., & Ahn, W. (2011). Designation of a new drug as a controlled substance. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2011.54.2.189
404. Lee, R. (2024). Opioid Use Disorder Industry: Role of Recent Trends in Transformation of the Sector. Clinical Case Reports and Studies. https://doi.org/10.59657/2837-2565.brs.24.099
405. Lee, V. (2021). Mental Health Impacts during COVID-19. Journal of Anxiety & Depression. https://doi.org/10.46527/2582-3264.136
406. Lee, X.-C., Lu, T., Zheng, W., & Xue, Y. (2025). STRESS COMBINED WITH EXTINCTION PREVENTS COCAINE RELAPSE BY DISRUPTING MEMORY. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.175
407. Leitão, F., Pinho, S. A., Freitas, J., & Coutinho, F. (2024). Review of Delusional Jealousy and Its Association with Sexual Dysfunctions. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1582
408. Lervik, A., Haga, H. A., & Becker, M. (2010). Abnormal motor activity during anaesthesia in a dog: a case report. Acta veterinaria Scandinavica. https://doi.org/10.1186/1751-0147-52-64
409. Leucht, S., Samara, M., Rodolico, A., Bauer, I., Bäckers, L., & Bighelli, I. (2020). S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaa031.270
410. Levin, M. (2013). Opioids in Headache. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/head.12266
411. Levy, T., Silver, H., Soufer, R., Rouhandeh, A., Kolevzon, A., Buxbaum, J. D., & Siper, P. M. (2025). Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1526383
412. Levy, T., Silver, H., Soufer, R., Rouhandeh, A., Kolevzon, A., Buxbaum, J. D., & Siper, P. M. (2025). Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss. medRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2025.01.04.24318923
413. LeWitt, P. A., Dubow, J., & Singer, C. (2011). Is levodopa toxic?. Neurology. https://doi.org/10.1212/wnl.0b013e31823435a4
414. Leyde, S., & Azari, S. (2020). What Should I Know About Opioids and Living With Chronic Pain?. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.1679
415. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
416. Lim, H., Kwon, Y.-J., Lee, J.-E., & Cho, S. (2013). Reconsideration of Psychasthenia- Two Cases. Journal of Oriental Neuropsychiatry. https://doi.org/10.7231/jon.2013.24.3.245
417. Lim, R., & Campbell, W. G. (2009). A Categorical Framework for Addicted and Chronic Pain Opioid Users. The Canadian Journal of Addiction. https://doi.org/10.1097/02024458-200912000-00001
418. Limandri, B. J. (2018). Benzodiazepine Use: The Underbelly of the Opioid Epidemic. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20180521-03
419. Lin, S. (2019). Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz068
420. Lind, C. C. K., Carchedi, C. L. R., Staudenmeier, L. J. J., & Diebold, L. P. C. J. (2005). Atypical presentations of atypical antipsychotics.. PubMed.
421. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
422. Liu, J., & JunHong, Y. (2010). The signal transudations mechanism of opioid dependence and withdrawal. Xiandai shengwu yixue jinzhan.
423. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
424. Lobato, E. F. (2013). Persistent hiccup treated by hypnosis. Revista Médica de Minas Gerais. https://doi.org/10.5935/2238-3182.20130040
425. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
426. Lucassen, P., Ligthart, S. A., Kramers, C., & Speckens, A. (2021). [Why do patients find it difficult to discontinue their medication?]. PubMed.
427. Madan, A., Frueh, B. C., Fowler, J. C., Stomberg, S., Bradshaw, M. R., Kelly, K. R., Weinstein, B., Luttrell, M., Danner, S. G., & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217420906659
428. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
429. Mahgoub, Y., Laux, T., Singh, J., & Francis, A. (2021). Polydipsia as a manifestation of catatonia: Case series. Journal of Affective Disorders Reports. https://doi.org/10.1016/j.jadr.2021.100074
430. Mahon, S. M., & Carr, E. (2021). Fatigue/Lack of Endurance: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.25
431. Maila, B., Tsarkov, A., Petlovanyi, P., Kweku, G., & Musonda, E. (2020). Treatment of Opioid Use Disorder With Buprenorphine-Naloxone at Chainama Hills College Hospital in Lusaka, Zambia: A Case Report. European Journal of Medical and Health Sciences. https://doi.org/10.24018/ejmed.2020.2.4.413
432. Maila, B., Tsarkov, A., Petlovanyi, P., Kweku, G., & Musonda, E. (2020). Treatment of Opioid Use Disorder With Buprenorphine-Naloxone at Chainama Hills College Hospital in Lusaka, Zambia: A Case Report. SSRN Electronic Journal.
433. Maita, E., Bodavula, G., Bello, A., Chehade, R., & Kuchipudi, S. (2023). Injurious Fall in an Elderly Chronic Heroin Addict During a Syncopal Episode. Cureus. https://doi.org/10.7759/cureus.37736
434. Mameli, M. (2009). Controlling the persistence of drug-evoked plasticity in the mesolimbic dopamine system. https://doi.org/10.13097/archive-ouverte/unige:2138
435. Mancke, F., Kaklauskaitė, G., Kollmer, J., & Weiler, M. (2016). Psychiatric comorbidities in a young man with subacute myelopathy induced by abusive nitrous oxide consumption: a case report. Substance Abuse and Rehabilitation. https://doi.org/10.2147/sar.s114404
436. Mangas, M. C., & Feliu, M. R. (2012). P-890 - Acute psychosis induced by anabolic steroids. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)75057-5
437. Mannix, D., Mulholland, K., & Byrne, F. (2024). Caffeine-Induced Psychosis: A Case Report and Review of Literature. Cureus. https://doi.org/10.7759/cureus.66306
438. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
439. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
440. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
441. Marković, H., Nikolac, N., Tripković, M., Haluga-Golubović, I., & Čustović, Z. (2012). Connection between Addictive Behavior and Investing on the Stock Market in Croatia.
442. Martı́nez-Raga, J., & López-Cerveró, M. (2019). [Transition of adolescents with attention deficit/hyperactivity disorder. Implications for treatment of adults].. PubMed.
443. Maruiti, A. M. P., Yoneyama, B. C., & Esteves, R. Z. (2012). A prescrição de drogas psicoativas na atenção primária. 10º Congresso Internacional da Rede Unida.
444. Marvanová, M. (2016). Introduction to Parkinson disease (PD) and its complications. Mental Health Clinician. https://doi.org/10.9740/mhc.2016.09.229
445. Masdrakis, V. G., Turic, D., & Baldwin, D. S. (2013). Pharmacological Treatment of Social Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351960
446. Massaly, N., Morón, J. A., & Al‐Hasani, R. (2016). A Trigger for Opioid Misuse: Chronic Pain and Stress Dysregulate the Mesolimbic Pathway and Kappa Opioid System. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2016.00480
447. Mayet, S., Winstock, A., & Strang, J. (2012). Opioids: heroin, methadone, and buprenorphine. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0062
448. Mazet, P., Bouquerel, G., & Millier, C. L. (1981). [Psychological and psychiatric emergencies in child and adolescent. Specificity and diversity of the possible situations and responses (author's transl)].. PubMed.
449. McArdle, P., & Angom, B. (2012). Adolescent substance misuse: an update on behaviours and treatments. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.106.003327
450. McHugh, R. K. (2023). Psychiatric Comorbidities Among Persons Who Are Using Opioids. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780197618431.013.33
451. McKeen, M. J., & Quraishi, S. A. (2013). Clinical review of intravenous opioids in acute care. journal of Anesthesiology and Clinical Science. https://doi.org/10.7243/2049-9752-2-1
452. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
453. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
454. Meehan, T. J., Bryant, S. M., & Aks, S. E. (2010). Drugs of Abuse: The Highs and Lows of Altered Mental States in the Emergency.
455. Meena, D., Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v7i6.592
456. Mehdiratta, N., Kalita, S., & Hirsch, A. R. (2023). Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs. https://doi.org/10.14293/p2199-8442.1.sop-.ptttfx.v1
457. Mei, S., Li, J., Middlebrooks, E. H., Almeida, L., Hu, W., Zhang, Y., Ramírez-Zamora, A., & Chan, P. (2019). New Onset On-Medication Freezing of Gait After STN-DBS in Parkinson's Disease. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.00659
458. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
459. Melvin, C. L., Carey, T. S., Goodman, F., Oldham, J. M., Williams, J. W., & Ranney, L. M. (2008). Effectiveness of Antiepileptic Drugs for the Treatment of Bipolar Disorder: Findings from a Systematic Review. Journal of Psychiatric Practice. https://doi.org/10.1097/01.pra.0000333583.75741.8b
460. Menezes, M. C. D. C., Gonçalves, L. G. V., Chaves, S. C. D. S., Jaime, T. F. M., Oliveira, I. C. Z., Sobrinho, K. D. L., Oliveira, L. L. D., Araújo, J. V. L. D., Gurian, F. G., Soares, I. L. T., Nero, L. D., Pereira, P. H. D. O., Moraes, F. D. C., & Teixeira, G. P. (2023). MAIN CAUSES OF INTENTIONAL ACCIDENTS IN PEDIATRICS AND CLINICAL MANIFESTATIONS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593712308095
461. Merrick, M. T., Ford, D., & Houry, D. (2019). Early Childhood Trauma and Substance Misuse and Addiction. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190056810.003.0018
462. Metropulos, J. T., Goldstein, B. R., & Hodapp, B. (2022). Recognition and Treatment Challenges of Acute Clozapine Withdrawal Syndrome: A Case Report. Cureus. https://doi.org/10.7759/cureus.25765
463. Meza-Ruiz, W., & Zúñiga-Escobar, G. (2023). Hematoma cerebral intraparenquimatoso e intraventricular por cocaína: reporte de un caso. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272023000100064
464. Miličević, V. (2014). Utjecaj bolesti ovisnosti na usnu šupljinu.
465. Millard, H., Wilson, B. A., & Noordsy, D. L. (2015). Low-Dose Quetiapine Induced or Worsened Mania in the Context of Possible Undertreatment. The Journal of the American Board of Family Medicine. https://doi.org/10.3122/jabfm.2015.01.140105
466. Miller, D. D. (2007). Sedation with Antipsychotics: Manage, Don't Accept Adverse 'Calming' Effect. Current psychiatry.
467. Miller, N. S., & Oberbarnscheidt, T. (2017). DSM-5 Psychiatric Diagnoses and Opioid Use Disorder. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000310
468. Miller, S. C., & Frankowski, D. (2012). Prescription Opioid Use Disorder: A Complex Clinical Challenge: Understanding Patients' Aberrant Medication-Taking Behaviors Can Greatly Aid Treatment. Current psychiatry.
469. Mir, J. A., Mushtaq, B., & Mushtaq, O. A. (2022). Clinical case report on bipolar affective disorder, mania. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.007
470. Mitra, S. (2018). Opioid-induced hyperalgesia: Pathophysiology and clinical implications. Journal of Opioid Management. https://doi.org/10.5055/jom.2008.0017
471. Moalla, M., Sellami, R., Baati, I., Féki, I., & Masmoudi, J. (2018). Persistent Psychosis with âEcstasyâ Single Use.
472. Moalla, M., Sellami, R., Baati, I., Féki, I., & Masmoudi, J. (2018). Persistent Psychosis with Ã¢Â€Â˜EcstasyÃ¢Â€Â™ Single Use.
473. Mocanu, C., Cernea, D., Enache, M., & Deca, A. G. (2009). [General anesthesia in ophthalmology].. PubMed.
474. Mogali, S., & Comer, S. D. (2013). Treatment of Pain and Opioid Abuse. ACS symposium series. https://doi.org/10.1021/bk-2013-1131.ch004
475. Mohanty, I., Arunvikram, K., Sardar, K. K., Palai, S., Sahoo, G., & Patra, R. C. (2014). Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. https://doi.org/10.14202/vetworld.2014.299-305
476. Monteiro, M. I., Ferreira, A., Grebe, H., Gomes, L., & Costa, M. M. D. (2016). Psiquiátrico, aditivo ou orgânico:  um desafio nos adolescentes. DOAJ (DOAJ: Directory of Open Access Journals).
477. Montejo, Á. L. (2020). Novel Research in Sexuality and Mental Health. MDPI eBooks. https://doi.org/10.3390/books978-3-03943-357-5
478. Montejo, Á. L., Montejo, L., & Baldwin, D. S. (2018). The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. https://doi.org/10.1002/wps.20509
479. Moorthi, K., Pertin, S., & Radhika, P. (2023). Homoeopathy for obsessive-compulsive disorder: A case report. Indian Journal of Research in Homoeopathy. https://doi.org/10.53945/2320-7094.1117
480. Moudgil, K., Tsundue, T., & Ponnusankar, S. (2018). Atropine Induced Delirium in Organophosphate (OP) Insecticide Poisoning: A Case Report. Journal of Young Pharmacists. https://doi.org/10.5530/jyp.2018.10.54
481. Mude, G., Pise, S., Makade, K., Fating, R., & Wakodkar, S. (2021). Termiticidal Activity of Ethanolic and n- Hexane Leaf Extraction of Calotropis procera, Cannabis indica and Mentha longifolia Against a Higher Termite Microtomes obesi. Journal of Developing Drugs. https://doi.org/10.35248/2329-6631.21.10.206
482. Mula, M., Matteo, P., Basaglia, C., Favaretto, E., & Schwitzer, J. (2013). 2804 – Asenapine after clozapine: is possible?. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77392-9
483. Muliyala, K. P., Lima, C. A. D. M., & Chong, D. (2024). S9: Addictions in Later Life an Emerging Crisis. International Psychogeriatrics. https://doi.org/10.1017/s104161022400111x
484. Mullen, S. (2018). Major depressive disorder in children and adolescents. Mental Health Clinician. https://doi.org/10.9740/mhc.2018.11.275
485. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
486. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
487. Murray, R., Jones, P. B., Susser, E., Os, J. V., & Cannon, M. (2002). Foreword. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544118.002
488. Mushthi, D., Chakraborty, R., Chaudhury, S., & Singh, A. (2025). Olanzapine-induced akathisia treated with clozapine. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_268_24
489. Myers, C. K., Kallinicos, R., & Lucas, C. P. (2020). 192 Eye’ve Seen Enough: Oculogyric Crisis in a 13 year old Male Treated for Comorbid ADHD and Psychosis After Stopping Lisdexamphetamine. CNS Spectrums. https://doi.org/10.1017/s1092852920001078
490. Möller, H., Demyttenaere, K., Sacchetti, E., Rush, A. J., & Montgomery, S. (2003). Improving the chance of recovery from the short- and long-term consequences of depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200307000-00004
491. Müller, C. P. (2013). Episodic Memories and Their Relevance for Psychoactive Drug Use and Addiction. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2013.00034
492. Müller, D., Angerer, V., Kithinji, J., Auwärter, V., Neurath, H., Liebetrau, G., Just, S., & Hermanns‐Clausen, M. (2016). Desoxypipradrol – eine neue (alte) Designerdroge. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-0042-107537
493. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
494. Navarro, I. V., Portilla, N. O., Gonzalez-Coloma, S., Higes, J. L., Cortés, M. M., González, P. G., & Olmo-Romero, F. D. (2014). EPA-0512 – Multidisciplinary approach in patients with severe pshychotic illness. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)77914-3
495. Nazlı, Ş. B., & Sevindik, M. (2020). Use of methylphenidate in co-existing major depression and loss of libido and erectile dysfunction: a case report. Anatolian Journal of Psychiatry. https://doi.org/10.5455/apd.112405
496. Neavins, T. M., Easton, C. J., Brotchie, J., & Carroll, K. M. (2008). Empirically validated psychological therapies for drug dependence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544392.020
497. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
498. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
499. Nevels, R. M., Gontkovsky, S. T., & Williams, B. E. (2016). Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required.. PubMed.
500. Neyra-Ontaneda, D. (2017). Psicosis inducida por ayahuasca: reporte de un caso.. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v80i4.3241
501. Nidode, P., Natarajan, C., Rajathi, G., Deepika, M. R., Shinkre, R., & Chouhan, D. S. (2024). Opioid dependency and intervention: A critical examination of the neurobiological foundations. Multidisciplinary Reviews. https://doi.org/10.31893/multirev.2023ss013
502. Niederhofer, H. (2011). Efficacy of Duloxetine and Agomelatine Does Not Exceed That of Other Antidepressants in Patients With Autistic Disorder. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.10l01038blu
503. Niesink, R. J., & Laar, M. V. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00130
504. Nieusha, M., Hassanpoor, N., Taheri, A., & Latifi, A. (2018). Methamphetamine Abuse Retinopathy: a Case Report.
505. Norman, T. R. (2025). The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?. Exploration of neuroscience. https://doi.org/10.37349/en.2025.1006105
506. Nový, M. (2012). The Question of Deployment Length in Peacekeeping Missions. Vojenské rozhledy. https://doi.org/10.3849/2336-2995.21.2012.04.122-128
507. Nubukpo, P., & Clément, J.-P. (2013). Medical drug abuse and aging. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2013.0415
508. Nunes, J. T., Brigadeiro, D., Andrade, J., & Costa, A. P. D. (2017). Neuroleptic-induced Parkinsonism in Patient with Obsessive Compulsive Disorder: A Case Report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1063
509. Nuñez, M. B., Dhingra, A., Dhingra, M., Kossack, R., & Dhingra, M. (2022). Kratom's rising role in the potential exacerbation of mental health disorders: A case report and review of the literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100069
510. Oates, L. (2010). Complementary medicines for anxiety. Australian pharmacist.
511. Oetomo, A., Kandarini, Y., Widiana, R., & Ayu, N. P. (2021). POS-046 ACUTE KIDNEY INJURY IN AMPHETAMIN INTOXICATION. Kidney International Reports. https://doi.org/10.1016/j.ekir.2021.03.052
512. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
513. Oke, O., Sekh, M. B., Johnson, B. O., & Adeyemo, S. (2024). Methadone Withdrawal-Induced Psychosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.55256
514. Okoji, O. Y., Zeddun, S., & Borum, M. L. (2009). Suicidal ideation resulting from severe Inflammatory Bowel Disease symptoms. Inflammatory Bowel Diseases. https://doi.org/10.1097/00054725-200912002-00023
515. Olarte, J. M. N. (2008). Clinical pharmacology of opioids: adverse effects of opioids. CRC Press eBooks. https://doi.org/10.1201/b13440-14
516. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
517. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
518. Oluwole, L., Dada, M. U., & Obadeji, A. (2013). Self-inflicted bilateral orchidectomy precipitated by erotic bizarredelusions : a case report : scientific letters. African Journal of Psychiatry.
519. Omari, F. E., Berrada, H., Chebli, H., & Azraf, F. (2023). Depressive disorder comorbid with problematic alcohol use. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1374
520. Onda, K., Yukawa, T., Sakaue, M., Tsuboya, R., Inoue, E., & Someya, T. (2021). Withdrawal from long‐term use of caffeinated drinks can cause schizophrenia‐like symptoms: A case report. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13199
521. Ondrejka, I., Šnircová, E., Kulhan, T., & Nosálóvá, G. (2012). Atomoxetine in the Treatment of the Most Common Comorbid Disorders of Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder and Anxiety Disorders. Acta Medica Martiniana. https://doi.org/10.2478/v10201-011-0039-z
522. Osborn, C. J., & Iarussi, M. M. (2017). Addictions Counseling. Routledge eBooks. https://doi.org/10.4324/9781315537061-13
523. Oslin, D. W. (2007). Addictions. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-960-8_9
524. Ostwal, S., Salins, N., & Deodhar, J. (2017). Reversal of opioid-induced toxicity. Indian Journal of Palliative Care. https://doi.org/10.4103/ijpc.ijpc_117_17
525. Otten, R. I., Jansen, I., & Zeeman, M. (2019). [A vulnerable elderly man with prednisone-induced delirium].. PubMed.
526. Ozdemir, D., Allain, F., Kieffer, B. L., & Darcq, E. (2023). Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2023.109524
527. O’Dwyer, M., McCallion, P., McCarron, M., & Henman, M. (2018). Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research. Therapeutic Advances in Drug Safety. https://doi.org/10.1177/2042098618782785
528. Pai, N., & Vella, S. (2011). Reason for clozapine cessation. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2011.01776.x
529. Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.46079
530. Palijan, T. Ž., Kovačević, D., & Turcinović, M. K. (2007). Psychodynamic Characteristics of Ego in Alcoholic Offenders and Non-Offenders. Alcoholism Clinical and Experimental Research.
531. Pang, D., & Pucci, M. (2021). Medical Aspects of Drug and Alcohol Use. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623199.011
532. Pang, N. T. P., & Masiran, R. (2020). Mood disorder induced by prednisolone – an easily overlooked complication. Current Problems of Psychiatry. https://doi.org/10.2478/cpp-2020-0012
533. Papapetropoulos, S. (2011). Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2011.00253.x
534. Pappagallo, M. (1998). The Concept of Pseudotolerance to Opioids. Journal of Pharmaceutical Care in Pain & Symptom Control. https://doi.org/10.1300/j088v06n02_07
535. Parag, S., & Espiridion, E. D. (2018). Hyponatremia Presenting with Recurrent Mania. Cureus. https://doi.org/10.7759/cureus.3645
536. Pary, R., Lippmann, S., & Tobias, C. R. (1988). Depression and Alcoholism: Clinical Considerations in Management. Southern Medical Journal. https://doi.org/10.1097/00007611-198812000-00016
537. Passmore, M. J., Sheldon, L. J., Lax, S., Wilkins‐Ho, M., & Illing, M. (2009). ORAL MIDAZOLAM FOR DEMENTIA‐RELATED RESPONSE AGITATION. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02162.x
538. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
539. Patel, T., Chen, H., Michels, J., & Hata, J. (2016). Opioid-Induced Constipation: A Comprehensive Overview. https://doi.org/10.2310/pm.15036
540. Patterson, A., Malaty, I. A., Okun, M. S., & Martínez-Ramírez, D. (2016). A Case of Reemergent Punding and Impulse Control Disorder Associated with Levodopa-Carbidopa Intestinal Gel in Parkinson Disease (P4.326). Neurology. https://doi.org/10.1212/wnl.86.16_supplement.p4.326
541. Paul, M. A., & Teli, B. A. (2020). ADHD and Substance Abuse in Children and Adolescents. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-7998-5495-1.ch014
542. Paulozzi, L. J., Weisler, R. H., & Patkar, A. A. (2011). A National Epidemic of Unintentional Prescription Opioid Overdose Deaths: How Physicians Can Help Control It. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10com06560
543. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
544. Peixoto, C., Rêgo, D. C., Bicho, M., Coelho, J. M., & Medeiros, H. (2021). Delusional infestation: Two case reports. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.2034
545. Penders, T. M., Rohaidy, R., & Agarwal (2013). Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s43113
546. Peppin, J. F., Pergolizzi, J. V., Vortsman, E., & Raffa, R. B. (2021). Commentary: “Ockham’s Razor” Doesn’t Apply to “Opioid” Overdose Death. Journal of Biosciences and Medicines. https://doi.org/10.4236/jbm.2021.91008
547. Peppin, J. F., Raffa, R. B., & Schatman, M. E. (2020). &lt;p&gt;The Polysubstance Overdose-Death Crisis&lt;/p&gt;. Journal of Pain Research. https://doi.org/10.2147/jpr.s295715
548. Perera, V., Forrest, A., & Xu, J. (2014). High-Dose Olanzapine for Bipolar Depression. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.13l01620
549. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
550. Pergolizzi, J. V., Annabi, H., Gharibo, C., & LeQuang, J. A. (2018). The Role of Lofexidine in Management of Opioid Withdrawal. Pain and Therapy. https://doi.org/10.1007/s40122-018-0108-7
551. Pergolizzi, J. V., LeQuang, J. A., Berger, G. K., & Raffa, R. B. (2017). The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. Pain and Therapy. https://doi.org/10.1007/s40122-017-0068-3
552. Pergolizzi, J. V., Raffa, R. B., & Rosenblatt, M. (2020). Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.13114
553. Pergolizzi, J. V., Taylor, R., LeQuang, J. A., Bisney, J., Raffa, R. B., Pergolizzi, F., Colucci, D., & Batastini, L. (2018). Driving under the influence of opioids: What prescribers should know. Journal of Opioid Management. https://doi.org/10.5055/jom.2018.0474
554. Pergolizzi, J. V., Varrassi, G., LeQuang, J. A., & Raffa, R. B. (2021). The Challenge of Polysubstance Use Overdose. Open Journal of Social Sciences. https://doi.org/10.4236/jss.2021.97038
555. Persinger, M. A. (2016). Answers to Two Questions Consistently Reflect Cerebral Dysfunction or Damage Subsequent to Mild Closed Head Injuries and Protracted Difficulties with Adaptation. Journal of Neurological Disorders. https://doi.org/10.4172/2329-6895.1000277
556. Perłowski, J., Miśkiewicz, M., Ptak, J., Noga, R., Teska, V., Marcinkowska, J., Herc, A., Koczkodon, K., Sawczuk, M., & Krompiewski, M. (2024). Recreational ketamine use and its impact on health. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.68.55185
557. Petersson, M., & Uvnäs‐Moberg, K. (2024). Interactions of Oxytocin and Dopamine—Effects on Behavior in Health and Disease. Biomedicines. https://doi.org/10.3390/biomedicines12112440
558. Petrosino, B., Signorelli, M. S., Lio, F. M. D. S., Petrosino, C., & Aguglia, E. (2016). The treatment of autism with pipamperone: A case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2027
559. Pfistermeister, B., Dormann, H., Patapovas, A., Meier, F., Müller, F., Sonst, A., Plank‐Kiegele, B., Vogler, R., Schöffski, O., Bürkle, T., & Maas, R. (2013). PP024—Adverse drug events and medication errors related to psychotropic drugs in patients presenting at an emergency department. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2013.07.059
560. Phillips, B., Shahid, M. H., Safa, H. I., Jian, W., Snyder, S., Turco, L., Hale, E., Weber, W. E., O’Connor, J., & Asensio, J. A. (2017). Challenges of Treating Methamphetamine-Positive Patients. Scholarly Journal of Emergency Medicine and Critical Care. https://doi.org/10.36959/592/372
561. Piazza, P. V., & Deroche‐Gamonet, V. (2013). A multistep general theory of transition to addiction. Psychopharmacology. https://doi.org/10.1007/s00213-013-3224-4
562. Pickard, H. (2011). What Is Personality Disorder?. Philosophy, psychiatry & psychology. https://doi.org/10.1353/ppp.2011.0040
563. Pina, I. B., Gorostiza, P. R., Yllán, P. V., & Fernández, J. V. (2000). [Persisting and late onset psychotic disorder due to consumption of ecstasy (MDMA)].. PubMed.
564. Pitel, A., & Segobin, S. (2023). Contribution of Thalamocortical Loops to the Development, Persistence, and Complications of Alcohol Use Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197676158.003.0069
565. Piwuna, C. G., Makput, D. M., & Wakil, M. A. (2015). Persistent delusional disorder in a 32 year old male. Highland Medical Research Journal.
566. Plaisance, C. J., Ledet, L. F., Slusher, N. J., Daniel, C. P., Lee, Z., Dorius, B., Barrie, S., Parker-Actlis, T. Q., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2024). The Role of Dopamine in Impulsivity and Substance Abuse: A Narrative Review. Health psychology research. https://doi.org/10.52965/001c.125273
567. Poewe, W., Olanow, C. W., Rascol, O., & Stocchi, F. (2020). From OFF to ON—Treating OFF Episodes in Parkinson’s Disease. touchREVIEWS in Neurology. https://doi.org/10.17925/usn.2020.16.suppl.1.2
568. Pohl, M., & Smith, L. T. (2012). Chronic Pain and Addiction: Challenging Co-occurring Disorders. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2012.684621
569. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
570. Pomerleau, C. S. (1997). Co‐factors for smoking and evolutionary psychobiology. Addiction. https://doi.org/10.1111/j.1360-0443.1997.tb03371.x
571. Poorter, A. D. (2017). The effect of chronic Benzodiazepine use on consumer safety : accidents, injuries, and cognitive failures.
572. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
573. Poznic-Jesic, M., Ješić, A., Babovic-Filipovic, J., & Zivanović, O. (2012). Extrapyramidal syndromes caused by antipsychotics. Medicinski pregled. https://doi.org/10.2298/mpns1212521p
574. Prabha, Y. S. (2023). Stress as a Topic of Concern in Gut Health: A Review. UTTAR PRADESH JOURNAL OF ZOOLOGY. https://doi.org/10.56557/upjoz/2023/v44i123527
575. Prasad, S., Kumar, A., & Rajeswari, K. (2024). Episodic Bout of Shouting: A Rare Variant of Childhood Obsessive Compulsive Disorder (OCD). International Journal of Research and Review. https://doi.org/10.52403/ijrr.20240572
576. Prathima, P. R., Johnson, D. B., Suresh, R., Venkatnarayanan, R., & Ahammad, P. M. A. (2013). Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route. Research Journal of Pharmacology and Pharmacodynamics.
577. Preciados, P. S., & Sánchez, E. A. (2023). Weight gain as a secondary effect of Olanzapine, and its interference in treatment adherence: a case report.. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2153
578. Preiß, M., Rabl, U., Popper, V., Watzal, V., Treiber, M., Ivkic, D., Praschak-Rieder, N., Naderi‐Heiden, A., Fugger, G., Frey, R., Rujescu, D., & Bartova, L. (2023). Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1204009
579. Preuss, U. W., Wong, W., & Farren, C. K. (2014). Chapter 9: Bipolar Affective Disorders and Alcohol Dependence: Comorbidity, Consequences Consequences, and Treatment.
580. Priya, L., Cao, F., Jaskirat, S., Jeffery, M., & Muhammad, F. (2021). Opioid Pseudoaddiction in a Patient with Long-Term Oxycodone Use for Chronic Pain. Journal of Clinical Anesthesia and Pain Management. https://doi.org/10.36959/377/353
581. Proczkowska‐Björklund, M., Gustafsson, P., & Svedin, C. G. (2010). Children’s play after anaesthesia and surgery: background factors and associations to behaviour during anaesthetic induction. Journal of Child Health Care. https://doi.org/10.1177/1367493509359225
582. Przewłocki, R. (2017). Mechanisms of opioid analgesics addiction. Palliative Medicine in Practice.
583. Pulia, M. S., & Richmond, J. S. (2013). The patient with post-traumatic stress disorder in the emergency department. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.016
584. Pérez, J. M. C., & Orellana, G. (2007). [Update in the clinic of addictions: learning and dopamine].. PubMed.
585. Pérez‐Mañá, C., Papaseit, E., Fonseca, F., Farré, A., Torrens, M., & Farré, M. (2018). Drug Interactions With New Synthetic Opioids. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.01145
586. Păunica, S., Giurgiu, M., Vasilache, A., Păunică, I., Motofei, I. G., Vasilache, A., Dumitriu, H., & Dumitriu, A. S. (2016). Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. https://doi.org/10.22543/2392-7674.1039
587. Queiroz, A. P. D. S., Pedro, M. O. P., Campos, M. W., Torales, J., Ventriglio, A., & Castaldelli-Maia, J. M. (2025). Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurology International. https://doi.org/10.3390/neurolint17070107
588. Radhakrishnan, R., Wilkinson, S. T., & Dâ€TMSouza, D. C. (2014). Gone to Pot â€“ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00054
589. Radovanovi, M. R., Milovanovi, D. R., & Radovanovi, M. S. (2012). Heroin addict with gangrene of the extremities, rhabdomyolysis and severe hyperkalemia Heroinski zavisnik sa gangrenom ekstremiteta, rabdomiolizom i teškom hiperkalemijom.
590. Rahman, S., Mohiuddin, S., & Hua, L. L. (2013). Seizures Secondary to Bupropion Misuse/Abuse: Three Cases. Adolescent Psychiatry. https://doi.org/10.2174/2210676611303020013
591. Raja, M., & Azzoni, A. (2009). Suicidal Ideation Induced by Episodic Cannabis Use. Case Reports in Medicine. https://doi.org/10.1155/2009/321456
592. Ramallo, V. J. G., Castaño, J. G., Perez, J., Llorente, B. P., Cervera, J. D. T., & Míguez, A. M. (1996). [Cocaine-induced neurological complications].. PubMed.
593. Ramchandani, V. A., Slattum, P. W., Patkar, A. A., Wu, L., Lee, J., Mohanty, M., Coe, M. A., & Li, T. (2014). Psychopharmacology and the Consequences of Alcohol and Drug Interactions. https://doi.org/10.1002/9781118430965.ch12
594. Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011). Marijuana Dependence: Not Just Smoke and Mirrors. ILAR Journal. https://doi.org/10.1093/ilar.52.3.295
595. Ramos, B. R. M., Martins, F. S., & Osório, E. (2022). Psychotic Cannabis Withdrawal: A Clinical Case. Cureus. https://doi.org/10.7759/cureus.31465
596. Ramos, T. M. B., Silva, R. R. D., Xavier, M., Santos, T. S. D., Lira, J. V. D., Costa, S. P., Silva, J. K. D. S., Silva, Á., Pontes, A., Silva, V. M. T., & Júnior, J. U. F. G. (2025). O USO DE PSICOTRÓPICOS RELACIONADO A QUALIDADE DO SONO DA PESSOA IDOSA. Revista Foco. https://doi.org/10.54751/revistafoco.v18n6-202
597. Rana, A. Q., Nadeem, A., Yousuf, M. S., & Kachhvi, Z. M. (2013). Late onset of atypical paroxysmal non-kinesigenic dyskinesia with remote history of Graves’ disease. Journal of Neurosciences in Rural Practice. https://doi.org/10.4103/0976-3147.120226
598. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
599. Rao, R., Kathiresan, P., Joshi, T., Bhad, R., Bhatnagar, S., Deb, K., & Chadda, R. (2020). Chronic noncancer pain and opioid addiction: Diagnostic and management challenges. Indian Journal of Palliative Care. https://doi.org/10.4103/ijpc.ijpc_232_19
600. Rao, T. S. (2018). Psychosocial therapies in addictive disorders. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.224346
601. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
602. Redondo, M. L., Domínguez, A. D., Domínguez, R. D., Díaz, L. M., Montero, C. G., Monge, M. P., Brasas, F. D. L. T., & Hernández, N. E. (2016). Opioids consumption and delusional symptomatology. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1351
603. Ree, J. M. V., Koob, G. F., Higgins, G. A., Naranjo, C. A., & Zvartau, E. (1995). Neurohormonal Systems Underlying Drug Addiction: Relevance for Treatment Strategies. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7218-8_27
604. Reginaldi, D., Tondo, L., Floris, G., Pignatelli, A. C., & Kukopulos, A. (1981). Poor Prophylactic Lithium Response due to Antidepressants. International Pharmacopsychiatry. https://doi.org/10.1159/000468484
605. Regnard, C., Kindlen, M., & Nichol, T. (2018). Helping the anxious person. CRC Press eBooks. https://doi.org/10.1201/9781315376363-29
606. Reinhold, J. A., Mandos, L. A., Lohoff, F. W., & Rickels, K. (2012). Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2012.721776
607. Riaz, A., Shahid, Q., Yousaf, H. M., Gul, U., Shah, S. S., Hidayat, A., Hamid, T., Rahman, A. U., Usman, M., Khan, M. K., Muhtiar, R., & Khalid, B. (2024). Mirtazapine in Primary Insomnia: Case report and Literature review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2024.23.1.2213
608. Rickels, K., & Downing, R. (2024). Nonspecific Factors and Drug and Placebo Response in Psychiatry. Routledge eBooks. https://doi.org/10.4324/9781032632841-20
609. Riley, M. A., Ahmed, S., & Locke, A. (2016). Common Questions About Oppositional Defiant Disorder.. PubMed.
610. Riquino, M. R., Priddy, S. E., Howard, M. O., & Garland, E. L. (2018). Emotion dysregulation as a transdiagnostic mechanism of opioid misuse and suicidality among chronic pain patients. Borderline Personality Disorder and Emotion Dysregulation. https://doi.org/10.1186/s40479-018-0088-6
611. Rizwana, S. R. S., Josna, T. J. T., & G.V.Nagaraju, G. (2019). CASE STUDY ON DEPRESSION. International Journal of Indigenous Herbs and Drugs.
612. Robertson, S., Peacock, E. E., & Scott, R. M. (2023). Benzodiazepine Use Disorder: Common Questions and Answers.. PubMed.
613. Rodnitzky, R. L., & Narayanan, N. S. (2013). Amantadine's role in the treatment of levodopa-induced dyskinesia. Neurology. https://doi.org/10.1212/wnl.0000000000000068
614. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
615. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
616. Rodríguez, F. D., Sánchez, M. L., & Coveñas, R. (2023). Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108656
617. Rodríguez, M., Mayo, L. F., Rodrigo, D. B., García, E. B., Torres, I. F., Pérez, V. D. A., Sanchez, C. M., & García, M. S. (2022). Sleep Disorders and Dual Disorders. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1183
618. Roh, H. S., Park, B. R., Jang, E. Y., Kim, J. S., & Gwak, Y. S. (2018). Acupuncture on the Stress-Related Drug Relapse to Seeking. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/5367864
619. Rojas-Jara, C., Calquin, F., González, J., Santander, E., & Vásquez, M. (2020). Negative effects of the use of benzodiazepines in older adults.
620. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
621. Roncero, C., López-Ortiz, C., Fora, F., Gálvez-Ortiz, V., Cardoner, N., Crespo-Blanco, J. M., Navarro-Odriozola, V., García–Parés, G., Sánchez-Pérez, M., Eucb, G., & Psiquiatría-CAS, S. D. (2011). Bupropion and dual pathology.
622. Roques, B. (2000). La dangerosité des drogues : mécanismes neurobiologiques des addictions et approches thérapeutiques.. médecine/sciences. https://doi.org/10.4267/10608/1588
623. Rosentreter, A., Dietlein, T. S., & Lappas, A. (2016). Umsetzung und Schwierigkeiten bei Tropftherapien – der ältere Glaukompatient im Fokus. Klinische Monatsblätter für Augenheilkunde. https://doi.org/10.1055/s-0041-110447
624. Ross, K., LaPointe, L. L., & Katz, R. C. (2010). Risk Factors for Depression in Aphasia: Clinical Implications.
625. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
626. Ruiz, P. D. J., & Logroño, J. F. (2017). Behavioral disorders: Within the limits of psychiatry or neurology? About a case. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1375
627. Ruzicka, D. L. (2018). Preserving Consciousness at the End of Life. Ethics & Medics. https://doi.org/10.5840/em201843915
628. Rybakowska, I. (2021). Psychoactive Substances and Drugs-Medicament and Narcotic. American Journal of Biomedical Science & Research. https://doi.org/10.34297/ajbsr.2021.12.001703
629. Rymowicz, R., & Tsuang, T. (2021). Hallucinogen Persisting Perception Disorder Following Recreational Dextromethorphan Use. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000287
630. Saini, S., Shandil, A., & S.K., E. (2012). Recent Therapies in Depression. InTech eBooks. https://doi.org/10.5772/33335
631. Salaam, A. O. (2005). Contributions of negative reinforcement processes to compulsive drug use. IFE PsychologIA. https://doi.org/10.4314/ifep.v13i2.23686
632. Salani, D., Goldin, D., Valdes, B., & Santis, J. P. D. (2023). The Price of Gambling: Examining Gambling Disorders. Issues in Mental Health Nursing. https://doi.org/10.1080/01612840.2023.2232862
633. Salazar, J. Z., Urrea, S. L., Tuirán, L. C. V., Solarte, D. M. E., Roldán, J. F. O., Ojeda, A. N. E., Motta, J. A. S., Guerrero, A. X. R., & García, O. A. B. (2024). Síndrome de Abstinencia a los Opioides. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i6.15033
634. Salazar, J. Z., Urrea, S. L., Tuirán, L. C. V., Solarte, D. M. E., Roldán, J. F. O., Ojeda, A. N. E., Motta, J. A. S., Guerrero, A., & García, O. A. B. (2024). Síndrome De Abstinencia A Los Opioides. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v8i6.14547
635. Salcedo, A. K. M., Escobar, J. C. C., & Diaz, L. Y. V. (2019). Ansiedad dental en adultos en la clínica odontológica de la universidad cooperativa de colombia de pasto.
636. Salge, H. (2011). Dysmorphophobie. Aktuelle Dermatologie. https://doi.org/10.1055/s-0030-1256839
637. Salinsky, L. M., Merritt, C. R., Zamora, J. C., Giacomini, J. L., Anastasio, N. C., & Cunningham, K. A. (2023). μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1239159
638. Salkind, A. R., & Hewitt, C. C. (1997). Coma from long-term overingestion of isoniazid.. PubMed.
639. Salman, S., Abdullah, A., Idrees, J., & Shah, F. H. (2016). How Community Pharmacists can Help Patients on Antidepressants at Risk for Suicides and Sexual Dysfunction. Journal of Pharmacy Practice and Community Medicine. https://doi.org/10.5530/jppcm.2016.3.8
640. Salmon, J. M., & Forester, B. P. (2012). Substance Abuse and Co-occurring Psychiatric Disorders in Older Adults: A Clinical Case and Review of the Relevant Literature. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2012.648439
641. Sam, S. S., & Torres, M. J. (2024). Drug Abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197584569.003.0096
642. Samudra, M., Gupta, N., Dhamija, S., Chaudhury, S., & Saldanha, D. (2021). A rare case of modafinil dependence presenting as sleep disorder. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.328856
643. Sandhu, H., Underwood, M., Furlan, A. D., Noyes, J., & Eldabe, S. (2018). What interventions are effective to taper opioids in patients with chronic pain?. BMJ. https://doi.org/10.1136/bmj.k2990
644. Sansone, R. A., & Sansone, L. A. (2010). Hoarding: obsessive symptom or syndrome?. PubMed.
645. Sansone, R. A., & Sansone, L. A. (2010). Medically Unexplainable Somatic Symptoms: A Coat With Many Psychiatric Colors. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.09l00879gre
646. Sanxhaku, D., Kodra, V., Alikaj, V., Allkoja, B., & Zenelaj, B. (2017). Child obsessive-compulsive disorder presenting with catatonic-like features: Case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.461
647. Saper, J. R., & Lake, A. E. (2008). Continuous Opioid Therapy (COT) is Rarely Advisable for Refractory Chronic Daily Headache: Limited Efficacy, Risks, and Proposed Guidelines. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2008.01153.x
648. Saperia, J., Lakhanpaul, M., Kemp, A., & Glaser, D. (2009). When to suspect child maltreatment: summary of NICE guidance. BMJ. https://doi.org/10.1136/bmj.b2689
649. Sarkar, S. (2018). Comment on psychiatric morbidity in opioid dependence. Indian Journal of Social Psychiatry. https://doi.org/10.4103/ijsp.ijsp_3_18
650. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
651. Sawyer, R. J., & Sansone, R. A. (2012). A Case of Sleep Masturbation Related to Dopamine Agonist Therapy. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01264
652. Sayeed, N., Kumar, V., & Muhammed, S. T. (2024). Neuropsychological Functioning in Patients with Opioids Dependence during Early Abstinence: A Comparative Study. Eastern Journal of Psychiatry. https://doi.org/10.5005/jp-journals-11001-0074
653. Sayyah, M., Majzoob, S., & Sayyah, M. (2013). Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.783011
654. Schaefer, C., Tome, M. E., & Davis, T. P. (2017). The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. Fluids and Barriers of the CNS. https://doi.org/10.1186/s12987-017-0080-3
655. Schepis, T. S., Rao, U., Yadav, H., & Adinoff, B. (2011). The Limbic-Hypothalamic-Pituitary-Adrenal Axis and the Development of Alcohol Use Disorders in Youth. Alcoholism Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2010.01380.x
656. Schneider, L. S. (2012). F4-02-01: Prescribing drugs for psychosis and agitation may cause more harm than good: A systematic review of effectiveness, expert opinion and societal concern. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2012.05.1629
657. Schneier, F. R., Bruce, L. C., & Heimberg, R. G. (2014). Social Anxiety Disorder (Social Phobia). American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg18
658. Schnoll, S. H., & Weaver, M. F. (2003). Addiction and Pain. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00554.x
659. Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. New England Journal of Medicine. https://doi.org/10.1056/nejmra1604339
660. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
661. Scuvée‐Moreau, J. (2013). [Neurobiology of addiction].. PubMed.
662. Segal, M. S. (2019). Cannabinoids and Analgesia. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-6
663. Sehgal, N., Colson, J. D., & Smith, H. S. (2013). Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2013.846517
664. Seim, L. A., Vijapura, P., Pagali, S. R., & Burton, M. C. (2020). Common substance use disorders in older adults. Hospital Practice. https://doi.org/10.1080/21548331.2020.1733287
665. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
666. Sellami, R., Messedi, N., Féki, I., Baâti, I., Zahaf, A., & Masmoudi, J. (2016). Zolpidem abuse: About a case. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1056
667. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
668. Shah, A. A., & Zaky, C. S. (2023). Addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197584521.003.0040
669. Shahrokh, B. (2017). None. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.3.3
670. Shahrokh, B. E. K. (2017). Acute Versus Long-Term Care Strategies for Individuals in Treatment for Substance Use Disorders. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/ofoaj.2017.03.555611
671. Shahrokh, B. E. K. (2017). Acute Versus Long-Term Care Strategies for Individuals in Treatment for Substance Use Disorders. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2017.03.555611
672. Shamla, F., Chaudhury, S., & Saldanha, D. (2023). Clozapine-induced Delirium. Medical Journal of Dr D Y Patil Vidyapeeth. https://doi.org/10.4103/mjdrdypu.mjdrdypu_128_23
673. Sharawat, I. K., & Dawman, L. (2018). Toddler With Intermittent Abnormal Behavior. Pediatric Emergency Care. https://doi.org/10.1097/pec.0000000000001555
674. Sharma, S., Kumar, P., Raut, N., & Prasad, S. (2021). Psychotic symptoms in heroin withdrawal: A case report. Indian Journal of Case Reports. https://doi.org/10.32677/ijcr.2021.v07.i02.010
675. Sharma, S., Kumar, P., Singh, R., Sidhu, G., & Shah, K. (2021). Psychotic Symptoms in Heroin Withdrawal: A Case Report. Cureus. https://doi.org/10.7759/cureus.12620
676. Sharma, S., Nepal, B., Moon, C. S., Chabenne, A., Khogali, A., Ojo, C., Hong, E., Gaudet, R., Sayed-Ahmad, A., Jacob, A., Murtuza, M., & Firlit, M. L. (2014). Psychology of Craving. Open Journal of Medical Psychology. https://doi.org/10.4236/ojmp.2014.32015
677. Shear, K., Ginsberg, D., Roose, S. P., Lenze, E. J., Alexopoulos, G. S., & Hollander, E. (2005). Depression in the Elderly: The Unique Features Related to Diagnosis and Treatment. CNS Spectrums. https://doi.org/10.1017/s1092852900027176
678. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
679. Sheikhmoonesi, F. (2014). EPA-0058 – Delusional disorder in a man with anorexia nervosa: a case-report. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)77561-3
680. Sherman, D. S. (1988). Psychoactive Drug Misuse in Long-Term Care: Some Contributing Factors. Journal of Pharmacy Practice. https://doi.org/10.1177/089719008800100307
681. Shinohara, R. C., Inoue, K., Takayanagi, S., Furutaka, Y., Yamazaki, H., & Watanabe, S. (2025). Successful treatment with lithium carbonate for periodic psychosis of adolescence. Psychiatry and Clinical Neurosciences Reports. https://doi.org/10.1002/pcn5.70133
682. Shinohara, R. C., Oshima, T., Otsubo, T., Ariga, K., Ono, T., Muneoka, K., Umezu, H., & Mikami, N. (2024). Successful utilization of clozapine for a patient with treatment‐resistant schizophrenia after recurrent violent behavior. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12462
683. Shprecher, D., & Mehta, L. (2010). The syndrome of delayed post-hypoxic  leukoencephalopathy.. PubMed.
684. Siler, C., Fuller, W. C., Whaley, D., & Keating, J. L. (2023). Polypharmacy in Older Adults: A Case Study.. PubMed.
685. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
686. Silverman, S. M. (2021). Pain and Chemical Dependency. https://doi.org/10.2310/pm.15032
687. Silverstein, E., Basiru, T., Aulakh, M., Verzura, M. L., & Suarez, R. (2025). Management of Acute Onset Catatonia Postpartum in a Patient With a History of Major Depressive Disorder With Psychotic Features: A Case Report. Cureus. https://doi.org/10.7759/cureus.84392
688. Sinha, R. (2018). Stress and Addiction. Routledge eBooks. https://doi.org/10.4324/9781315689197-25
689. Sireesha, S. R., Boorla, V., & Bhogaraju, A. (2013). Prolonged delirium secondary to hypoxic ischemic encephalopathy following complete hanging. Archives of Mental Health. https://doi.org/10.4103/2589-9171.227665
690. Sirohi, S., Bakalkin, G., & Walker, B. M. (2012). Alcohol-induced plasticity in the dynorphin/kappa-opioid receptor system. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2012.00095
691. Sisk, C. L., & Romeo, R. D. (2019). Drugs and the Adolescent Brain. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195314373.003.0008
692. Smith, A. P., Law, P., & Loh, H. H. (1988). Role of Opioid Receptors in Narcotic Tolerance/ Dependence. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-990-1_13
693. Smith, H. S., Smith, J. M., & Seidner, P. (2012). Opioid-induced nausea and vomiting.. PubMed. https://doi.org/10.3978/j.issn.2224-5820.2012.07.08
694. Smyth, D., Duffy, R. M., Flynn, D., Quirke, L., Monks, S., & Kennedy, H. (2012). DUNDRUM-D: Developmental Understanding of Drug Misuse & Dependence..
695. SN, S., HU, G., Di, A., AS, A., & Abubakar, A. (2024). Suicidal attempt in a patient with gambling disorder: A rare case report. Ibom Medical Journal. https://doi.org/10.61386/imj.v7i2.459
696. Snidvongs, S., & Mehta, V. (2011). Recent advances in opioid prescription for chronic non-cancer pain. Postgraduate Medical Journal. https://doi.org/10.1136/pgmj.2010.112045
697. Sochacki, S. (2025). Hyperalgesia, allodynia, and eventual overdose: The problems with chronic opioid use. Journal of Opioid Management. https://doi.org/10.5055/jom.0891
698. Sonavane, S., Motwani, S., Karia, S., Desousa, A., & Hukumchand, A. (2023). Sexual Dysfunction with Antidepressants: A Clinical Review. Indian Journal of Private Psychiatry. https://doi.org/10.5005/jp-journals-10067-0143
699. Sosin, I., Mysko, G., Sergienko, O., Honcharova, O., Babenko, Y., & Minko, O. (2021). Method of relieving alcohol dysphoria in the structure of hypertoxic alcohol abuse state with compulsive craving manifestations. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1499
700. Spanagel, R., Tran, B. X., Reyes‐Gibby, C. C., DeBeck, K., Ibrahim, F., & Bonevski, B. (2016). Advances in Drug Addiction.
701. Stacy, M. (2009). Impulse control disorders in Parkinson's disease. F1000 Medicine Reports. https://doi.org/10.3410/m1-29
702. Starks, S., Turpin, M. A. C., Reed, B., & Grissom, M. (2024). Addiction Medicine: Benzodiazepine Use Disorder.. PubMed.
703. Steininger, S. C., Frizi-Roser, R., Schneider, S., Hoang, T., & Zetzsche, D. A. (2024). Underrated and Underestimated – Deprivation in Dementia. A Case Report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1321
704. Stephen, S., & Bailey, C. (2013). Managing disruptive behaviour disorders in children.. PubMed.
705. Stewart, J. (2003). Stress and Relapse to Drug Seeking: Studies in Laboratory Animals Shed Light on Mechanisms and Sources of Long‐Term Vulnerability. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00535.x
706. Stewart, J. L., May, A. C., & Paulus, M. P. (2019). Bouncing back: Brain rehabilitation amid opioid and stimulant epidemics. NeuroImage Clinical. https://doi.org/10.1016/j.nicl.2019.102068
707. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
708. Stringaris, A., & Krieger, F. (2013). Bipolar disorder and disruptive mood dysregulation in children and adolescents: assessment, diagnosis and treatment. Evidence-Based Mental Health. https://doi.org/10.1136/eb-2013-101400
709. Stringer, J. D. (2016). Gender and Sexual Health: Sexual Dysfunction.. PubMed.
710. Sullivan, M. D. (2018). Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction. Clinical Journal of Pain. https://doi.org/10.1097/ajp.0000000000000603
711. Sullivan, M. D., & Ballantyne, J. C. (2020). When Physical and Social Pain Coexist: Insights Into Opioid Therapy. The Annals of Family Medicine. https://doi.org/10.1370/afm.2591
712. Sun, H. L. (1998). Naloxone. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199811000-00057
713. Sun, H. L. (1998). Naloxone. Anesthesia & Analgesia. https://doi.org/10.1213/00000539-199811000-00057
714. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
715. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
716. Supp, G. G., Higgen, F. L., Hipp, J. F., Engel, A. K., & Siegel, M. (2018). Mid-Latency Auditory Evoked Potentials Differentially Predict Sedation and Drug Level Under Opioid and Hypnotic Agents. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2018.01427
717. Sussman, S. (2025). Vulnerability to addictive behaviors: the Associational Memory‐Appetitive Systems Relations Model. World Psychiatry. https://doi.org/10.1002/wps.21283
718. Swayamprava, S., Giri, H. C., Ojha, S. K., & Niranjan (2024). Understanding of Alcohol use disorder in Ayurveda. International Journal For Multidisciplinary Research. https://doi.org/10.36948/ijfmr.2024.v06i05.27493
719. Szabó, P., & Szászi, B. (2021). [Body dysmorphic disorder: One Hundred Years of Solitude].. Psychiatria Hungarica.
720. Sáiz, P. A., García‐Portilla, M. P., Barrondo, S. M., Bascarán, T., García, M. B., & Bobes, J. (2003). Complicaciones psicopatológicas asociadas al consumo de drogas recreativas. Adicciones. https://doi.org/10.20882/adicciones.463
721. Sánchez-Pérez, M., Roncero, C., Gálvez-Ortiz, V., Cardoner, N., Crespo-Blanco, J. M., Navarro-Odriozola, V., García–Parés, G., Eucb, G., & Psiquiatría, S. D. (2011). Use of bubropion in elderly patients.
722. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
723. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17-2-39
724. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17.2.39
725. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
726. Taoufiq, P. I. (2024). Cognitive behavioral therapy for a case of addiction with personality disorder (clinical case study). ARID International Journal of Social Sciences and Humanities. https://doi.org/10.36772/arid.aijssh.2024.s.69
727. Tariq, F. (2012). Premature Ejaculation Re-Visited: Definition and Contemporary Management Approaches. InTech eBooks. https://doi.org/10.5772/25670
728. Tawfic, Q. A., Faris, A. S., & Date, R. (2013). The Dilemma of Opioid-Induced Hyperalgesia and Tolerance in Chronic Opioid Therapy = معضلة فرط التألم و حالة التحمل الناتج عن العلاج طويل الأمد بالأدوية ( المسكنات ) الأفيونية. Sultan Qaboos University medical journal. https://doi.org/10.12816/0003220
729. Taylor, J. L., & Samet, J. H. (2022). Opioid Use Disorder. Annals of Internal Medicine. https://doi.org/10.7326/aitc202201180
730. Teixeira, M. Z. (2013). Rebound effects of modern drugs: serious adverse events unknown by health professionals. Revista da Associação Médica Brasileira (English Edition). https://doi.org/10.1016/s2255-4823(13)70530-7
731. Tepper, S. J. (2012). Opioids Should Not Be Used in Migraine. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2012.02140.x
732. Thakkar, K., Shah, K., Rana, D., Malhotra, S., & Patel, P. (2017). Amlodipine drug therapeutic failure: a rare case report. International Journal of Basic & Clinical Pharmacology. https://doi.org/10.18203/2319-2003.ijbcp20175700
733. Thakrar, A. P., & Rastegar, D. A. (2025). Opioids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0006
734. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
735. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
736. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
737. Tiffon, B.-N. (2022). Borderline Personality Disorder. CRC Press eBooks. https://doi.org/10.4324/9781003092223-8
738. Tobias, J., & Gopalakrishnan, S. (2012). Premedication: Is clonidine the answer?. Saudi Journal of Anaesthesia. https://doi.org/10.4103/1658-354x.93041
739. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
740. Tollefson, G. D., Rampey, A. H., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W. K., & Genduso, L. A. (2022). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203822937-24
741. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
742. Torrens, M., Martínez-Sanvisens, D., Martinez-Riera, R., Bulbena, A., Szerman, N., & Ruiz, P. (2011). Dual Diagnosis. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0b013e318215f322
743. Trawka, P., Husejko, J., & Kędziora‐Kornatowska, K. (2021). Clinical consequences of abuse and misuse of hypnotics and analgesics in geriatric population. Ból. https://doi.org/10.5604/01.3001.0015.3853
744. Trujillo, K. A. (2012). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence A Review of the Research, A Cellular Model, and Implications for the Treatment of Pain and Addiction.
745. Tucker, M. G., Kekulawala, S., Kent, M., Mostafa, S., & Harvey, R. (2016). Polysubstance-induced relapse of schizoaffective disorder refractory to high-dose antipsychotic medications: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-016-1031-3
746. Turillazzi, E., Perilli, G., Paolo, M. D. P., Neri, M., Riezzo, I., & Fineschi, V. (2011). Side Effects of AAS Abuse: An Overview. Mini-Reviews in Medicinal Chemistry. https://doi.org/10.2174/138955711795445925
747. Twycross, R. (1975). The use of narcotic analgesics in terminal illness. Journal of Medical Ethics. https://doi.org/10.1136/jme.1.1.10
748. Tyler, R. E., & Leggio, L. (2024). Biological basis of addiction and alcohol use disorder. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000177
749. Uddin, M. S., Sufian, M. A., Kabir, M. T., Hossain, M. F., Nasrullah, M., Islam, I., Mamun, A. A., Islam, M. T., & Khanum, S. (2017). Amphetamines: Potent Recreational Drug of Abuse. Journal of Addiction Research & Therapy. https://doi.org/10.4172/2155-6105.1000330
750. Ungar, A. K., Konova, A. B., Patel, A. N., Goldstein, R. Z., & Hurd, Y. L. (2016). Substance Use and Addictive Disorders. https://doi.org/10.1002/9781118654231.ch16
751. Upadhyay, S., Elmatite, W., Taqi, S., Jagia, M., & Mallick, P. (2011). Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian Journal of Palliative Care. https://doi.org/10.4103/0973-1075.92353
752. Upadhyaya, H. P. (2007). Managing ADHD in the Presence of Comorbid Substance Use Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.0607e15
753. Urakov, T., & Hart, R. (2017). Intoxicants. Routledge eBooks. https://doi.org/10.4324/9781315382760-68
754. Urban‐Kowalczyk, M., Rudecki, T., Wróblewski, D., & Rabe‐Jabłońska, J. (2012). [Psychotic disorders related with chronic use of mephedrone. Case report].. PubMed.
755. Vadivelu, N., Mitra, S., Kai, A., Kodumudi, G., & Gritsenko, K. (2016). Review of perioperative pain management of opioid-dependent patients. Journal of Opioid Management. https://doi.org/10.5055/jom.2016.0344
756. Vahabzadeh, M., & Mégarbane, B. (2020). Abdominal pain related to adulterated opium: An emerging issue in drug addicts. World Journal of Psychiatry. https://doi.org/10.5498/wjp.v10.i5.95
757. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
758. Vasconcelos, F. D. C. J. (2015). Bipolar patients with alcohol consumption will have more relapses?: a 5 year follow-up study.
759. Vasoconstriction, C., Nguyen, K. D., López, I. A., & Ishiyama, G. (2014). Review of Opioid-Associated Hearing Loss and Possible Mechanism of Opioid-Mediated Endothelin-1-Dependent.
760. Vašková, J., Kočan, L., & Vaško, L. (2016). Oxidative Stress and Opioids. Global Journal of Anesthesiology. https://doi.org/10.17352/2455-3476.000027
761. Vearrier, D., & Grundmann, O. (2021). Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1923
762. Velásquez-Martínez, M. C., & Ortíz, J. G. (2014). Abuso de Drogas: Generalidades Neurobiológicas y Terapéuticas. Actualidades en Psicología. https://doi.org/10.15517/ap.v28i117.14135
763. Vergauwen, K. (2024). Physical activity, participation and health-related quality of life in chronic fatigue syndrome and multiple osteochondromas. https://doi.org/10.26481/dis.20240425kv
764. Verma, R., Kumar, N., & Kuppili, P. P. (2018). Repetitive Transcranial Magnetic Stimulation. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.17l02199
765. Verma, S., & Agrawal, R. (2021). The lasting effects of childhood trauma. Current psychiatry. https://doi.org/10.12788/cp.0101
766. Verster, J. C., Volkerts, E. R., Spence, D. W., Alford, C., & Pandi‐Perumal, S. R. (2007). Effects of Sleep Medications on Cognition, Psychomotor Skills, Memory and Driving Performance in the Elderly. Current Psychiatry Reviews. https://doi.org/10.2174/157340007782408860
767. Vicente‐Rodríguez, M., Herradón, G., & Pérez‐García, C. (2021). Toxicology of Drugs of Abuse. CRC Press eBooks. https://doi.org/10.1201/9780203730584-26
768. Vidić, M. (2018). Psihološki aspekti ovisnosti o psihoaktivnim tvarima.
769. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
770. Villegas-Pineda, M. H., & Palacio-García, C. A. (2016). Case report: Opioid tolerance and hyperalgesia after abdominal injury. Colombian Journal of Anesthesiology. https://doi.org/10.1016/j.rcae.2016.03.005
771. Virmani, A., Ali, S. F., & Binienda, Z. (2010). Neuroprotective strategies in drug abuse‐evoked encephalopathy. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05171.x
772. Vitale, C., Trojano, L., Barone, P., Errico, D., Agosti, V., Sorrentino, G., Grossi, D., & Santangelo, G. (2013). Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.. PubMed. https://doi.org/10.3233/ben-129024
773. Volkow, N. D., & Swanson, J. M. (2008). Does Childhood Treatment of ADHD With Stimulant Medication Affect Substance Abuse in Adulthood?. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.08020237
774. Vouk-Kamenski, J., Vukojević, J., & Ćelić, I. (2021). Successful Treatment of Delusional Infestation with Olanzapine Depot.. PubMed. https://doi.org/10.1530/alphapsychiatry.2021.21265
775. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
776. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
777. Wang, Z., Wang, Y., Yue, S., Yang, F., & Singh, A. (2025). EARLY SOCIAL ISOLATION STRESS POTENTIATES HEROIN SEEKING BY AGGRAVATING THE DYSFUNCTION OF PRELIMBIC CORTEX TO VENTRAL TEGMENTAL AREA PROJECTION. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.019
778. Wankhade, S. P., & Gibbs, J. (2024). Alcohol Dependence Syndrome With Bipolar Affective Disorder and Hypomanic Current Episode: A Case Report. Cureus. https://doi.org/10.7759/cureus.55994
779. Wdowiak, K., Maciocha, A., Julia, Witas, A., Drogoń, J., Chachaj, W., Słomka, P., Gwóźdź, E., Konieczko, D., & Gardocka, E. (2024). issue of recreational use of sildenafil. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.66.55563
780. Weas, S., & Barbaresi, W. J. (2025). ADHD Prescription Patterns: Paying Attention to Trends. PEDIATRICS. https://doi.org/10.1542/peds.2024-069093
781. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
782. Welliver, M., Bertrand, A., Garza, J., & Baker, K. A. (2012). Two New Case Reports of Propofol Abuse and a Pattern Analysis of the Literature. International Journal of Advanced Nursing Studies. https://doi.org/10.14419/ijans.v1i1.27
783. Wenbing, C., Asano, T., Notaka, I., Shin-Ichi, M., & Nitta, A. (2025). SUPPRESSION OF TENEURIN-4 IN THE NUCLEUS ACCUMBENS ALLEVIATES METHAMPHETAMINE-INDUCED DOPAMINE RELEASE AND BEHAVIORAL ALTERATIONS IN MICE. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.174
784. Wesson, D. R., Smith, D. E., Ling, W., & Sabnani, S. (2008). Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch64
785. Wettstein, R. M., & Kelly, J. (2016). A PHARMACOLOGICAL APPROACH TO SEXUALLY DEVIANT BEHAVIOR IN THE COMMUNITY.
786. White-Campbell, M. (2018). The older adult. CRC Press eBooks. https://doi.org/10.4324/9781315383491-11
787. Whitledge, J. D., Watson, C. J., Barbuto, A. F., Boyle, K. L., & Ganetsky, M. (2020). Toxicity of agents used for opioid withdrawal: a case-based approach. International Anesthesiology Clinics. https://doi.org/10.1097/aia.0000000000000265
788. Wick, J. Y., & Zanni, G. R. (2011). Helping Those with Hoarding Behaviors. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2011.458
789. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
790. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
791. Wit, L. E. D., Vis, R., & Teunissen, L. L. (2024). [Wakefulness-promoting agents for severe fatigue: to use or not to use?]. PubMed.
792. Wolfgang, A., Weimer, M. B., Na, P. J., Fiellin, D. A., & Muvvala, S. B. (2023). Long-Term Treatment of Opioid Use Disorder with Medications. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780197618431.013.23
793. Wong, M. K., Darvishzadeh, A., Maler, N. A., & Bota, R. G. (2016). Five Supplements and Multiple Psychotic Symptoms: A Case Report. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.15br01856
794. Woo, C. H., & Kim, S. (2014). Effectiveness of the Military Mental Health Promotion Program. Journal of Korean Academy of Nursing. https://doi.org/10.4040/jkan.2014.44.6.717
795. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
796. Wulandari, A., Kusuma, M. D., & Pancarani, R. (2023). Bipolar disorder - difficulties in managing emotional ups and down in an entertainer life: a case report. https://doi.org/10.35990/amhs.v1n3.p137-143
797. Xu, T., Li, Z.-S., Fang, W., Cao, L., & Zhao, G. (2022). Concomitant Othello syndrome and impulse control disorders in a patient with Parkinson’s disease: A case report. World Journal of Clinical Cases. https://doi.org/10.12998/wjcc.v10.i3.1024
798. Yadav, P. S., Pokhrel, P., Bhattarai, S., Adhikari, P., Dev, A., Upadhaya, A., & Chaudhary, S. (2024). Management of high dose olanzapine poisoning in a young child under limited resource setting: a case report from Nepal. Annals of Medicine and Surgery. https://doi.org/10.1097/ms9.0000000000002652
799. Yan, C., Taneja, K., & Tang, S. (2023). Obsessive compulsive disorder due to dexamethasone use. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100123
800. Yang, B.-K., Yi, S.-R., Ahn, Y.-J., Im, S. H., & Park, S. H. (2016). Ischial Tuberosity Avulsion Stress Fracture after Short Period of Repetitive Training. Hip & Pelvis. https://doi.org/10.5371/hp.2016.28.3.187
801. Yang, S., & Werner, B. C. (2018). Risk Factors for Prolonged Postoperative Opioid Use After Spinal Fusion for Adolescent Idiopathic Scoliosis. Journal of Pediatric Orthopaedics. https://doi.org/10.1097/bpo.0000000000001139
802. Yetkın, S., & Çor, S. A. (2023). Psychological Inflexibility in Depression with Psychotic Features: A Case Report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2180
803. Yilmaz, A., Bozkurt, M., & Evren, C. (2014). Alkol ve Madde Bağimliliğinda Remisyon ve Depreşme Remission and Relapse in Alcohol and Substance Addiction.
804. Zalpuri, I., Matzke, M., & Joshi, S. V. (2024). Obsessive-Compulsive Disorder in Children and Adolescents: Early Detection in Primary Care Settings. PEDIATRICS. https://doi.org/10.1542/peds.2024-069121
805. Zaman, M., Aljeshi, A., Kuraga, K., Bunni, S., Sarker, T., Kashif, A. W., Sathish, J., Abouzeid, H., Alouf, H., Chinthamraks, J., Krishnan, A., Patker, S., Talreja, S., & Pentapati, D. (2025). Recreational Drugs Addiction, Withdrawal and its Impact on the body: A Literature Review. Medical Research Archives. https://doi.org/10.18103/mra.v13i3.6295
806. Zheng, J.-W., Meng, S., Liu, W.-Y., Chang, X., & Shi, J. (2023). [Appropriate Use and Abuse of Sedative-Hypnotic Drugs].. PubMed. https://doi.org/10.12182/20230260302
807. Zillmer, E. A., Montenegro, L. M., Wiser, J., Barth, J. T., & Spyker, D. A. (1996). Neuropsychological sequelae in subacute home chlordane poisoning: Ten case studies. Archives of Clinical Neuropsychology. https://doi.org/10.1093/arclin/11.1.77
808. Zoorob, R., Kowalchuk, A., & Grubb, M. D. (2018). Buprenorphine Therapy for Opioid Use Disorder.. PubMed.
809. Zulkifli, N., Khuzaini, A. M., Aziz, A. A., & Awang, H. (2023). Trauma-related hallucination in an 8-year-old child with dissociative symptoms. Deleted Journal. https://doi.org/10.4103/mjp.mjp_10_23
810. Zweifel, H.-J., Browne, J. A., & Levine, J. M. (2021). A case of a mixed overdose involving kratom (Mitragyna speciosa) leading to serotonin syndrome. Medical Science and Discovery. https://doi.org/10.36472/msd.v8i12.626